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“It is not by the gray of the hair that one knows the age of the heart.” 
—Edward Bulwer-Lytton 
 
 
 
 
“Theory is when we know everything but nothing works.  
Praxis is when everything works but we do not know why.  
We always end up by combining theory with praxis:  
nothing works and we do not know why.” 
—Albert Einstein 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
ABSTRACT 
Rheumatoid arthritis (RA) is the prototype of chronic inflammatory 
disease associated with a 1.5-2 fold increased risk of cardiovascular disease (CVD) 
and premature mortality. Though traditional CVD risk factors are important in the 
pathogenesis of atherosclerosis in patients with RA, they do not fully explain the 
increased risk of CVD events observed in RA. This thesis aimed to explore further 
the mechanisms that could account for accelerated atherogenesis and CVD in RA. 
In the study of established RA disease, which included patients treated 
during one year with TNF-α inhibitors, n=162, or the anti-CD20 agent rituximab, 
n=53, anti-atherogenic apolipoprotein A1 increased after commencement of therapy; 
this increase was not agent-specific and paralleled a reduction in RA disease activity. 
At the same time, apolipoprotein B and the atherogenic index did not change 
significantly. These favorable effects may have a potential for at least short-term 
improvement in cardiovascular risk in RA. On the other hand, the biologic agents 
caused differential effect on serum levels of anti-phosphorylcholine (anti-PC) IgM, a 
promising atheroprotective biomarker. Thus, these antibodies increased on TNF-α 
inhibitors in contrast to treatment with rituximab. The contribution of biologic agents 
to beneficial or harmful CVD effects needs to be elucidated in future studies.  
In studies incorporating 114 participants with early RA, examined with 
high-resolution B-mode ultrasonography after five years of disease, the pro-
atherogenic apoB and apoB/apoA1-ratio were independently associated with 
unfavorable carotid outcomes, while a profitable effect was associated with the anti-
atherogenic, anti-inflammatory apoA1. Also, low anti-PC IgM levels longitudinally 
had an unfavorable association with the plaque presence at the end of observation. 
These results suggest that apolipoproteins and anti-PC antibodies may have 
independent roles in subclinical atherosclerosis in patients with RA. Further analysis, 
over a prolonged observation period more than 10 years, showed that the bilateral 
carotid plaques occurrence was associated with a subsequent CVD event. Early 
improvement of inflammation, pain and disability, measured as reductions in DAS28, 
VAS pain and the HAQ score the first year after RA diagnosis, as well as use of 
methotrexate were associated with a better CVD outcome. Longitudinal approach 
confirmed the association of low anti-PC IgM levels and, also, increasing oxidized 
LDL over first five years of RA disease with an adverse CVD outcome. 
In a large observational early RA cohort of 741 patients followed more 
than 10 years, we examined the relationships of inflammatory and novel biomarkers 
with incident CVD morbidity and all-cause mortality. The study outcomes were 
tracked through the Swedish Hospital Discharge and the National Cause of Death 
Registries. The factors associated with adverse outcomes differed in patients with 
disease onset before 65 years of old and those 65 years and older. The cumulative 
burden of inflammation over the first two years and the presence of RA disease 
related autoantibodies had a value for CVD and mortality prognosis in the younger 
patients, while a change in inflammatory markers the first year after diagnosis had a 
stronger effect in the older patients. Low-dose glucocorticoids increased but use of 
methotrexate decreased risk of poor outcomes in the elderly. These findings imply 
that age stratification could add to identification of patient-at-risk, and highlight the 
need to treat RA early and more aggressively to improve long-term outcomes. 
Taken together, these results emphasize the complexity of the associations 
between inflammation, anti-rheumatic therapies, atherosclerotic burden and CVD in 
RA. Further studies addressing indicators for cardiovascular prognosis are unmet 
needed.  
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1 GENERAL INTRODUCTION 
Rheumatoid arthritis (RA) is a chronic progressive systemic disorder characterized by 
inflammation in synovial joints. Erosive arthritis resembling RA has been described 
in skeletons from North America dating back as far as 6,500 years ago, and in 
paintings RA-like features could be seen from the 15th century onwards (395). 
Although its name was introduced in the 1850s by Dr Augustin Jacob Landré-
Beauvais (338), the first classification criteria were developed only 50 years ago 
(287). In industrialized countries, RA is the most common autoimmune inflammatory 
arthritis which affects 0.5-1.0% of adults, with 5–50 new cases annually per 100 000 
adults, diagnosis based on the 1987 revised American College of Rheumatology 
(ACR) criteria (5). Prevalence rises with age and is highest in women older than 65 
years (127). 
Evidence suggests that RA develops in three phases: an asymptomatic period of genetic 
risk, a pre-clinical period in which RA-related antibodies can be detected, and a clinical 
phase with acute signs and symptoms of inflammatory arthritis (192, 222). The time 
duration for early RA versus established RA varies widely in the literature; while early 
RA usually comprises a period of weeks to months, the term “established RA” is 
generally used to describe patients with disease duration of 2 years or more (166). The 
disease has a wide spectrum of manifestations that range from mild and limited to 
severe and disabling.  In addition to joints, extra-articular pathology may occur in up to 
30% of patients, involving skin, eyes, lungs, heart and vessels (397). The natural 
history of RA itself includes spontaneous remission, remission induced by medical 
treatment or continuously progressive disease despite medication. Hence, there is a 
clear need to identify efficient diagnostic and prognostic indicators of the disease. 
The pathogenesis of RA is not well understood. Genetic (HLA genes and PTPN22) 
and environmental factors likely contribute (25, 221), and autoimmune processes 
have been implicated, with chronic inflammation of the joint synovial membrane 
considered the central event in the pathophysiology. Smoking is the dominant 
environmental risk factor and doubles the risk of developing RA (45), and in the 
context of specific genes smoking may trigger RA-immune reactions to citrullinated 
proteins (193, 221). Other potential environmental risk factors include alcohol and 
coffee intake, vitamin D status, use of oral contraceptive, and low socio-economic 
status (85, 208). 
Rheumatoid arthritis is best considered a clinical syndrome spanning several disease 
subsets. These different subsets entail several inflammatory cascades, which all lead 
towards a final common pathway in which persistent synovial inflammation and 
associated damage to articular cartilage and underlying bone are present. One key 
inflammatory cascade includes overproduction and overexpression of tumor necrosis 
factor-alpha (TNF−α) (111). This pathway drives both synovial inflammation and 
joint destruction. TNF-α overproduction has several causes, including interactions 
between T and B lymphocytes, synovial-like fibroblasts, and macrophages. This 
process leads to overproduction of many cytokines, such as interleukin-1 (IL-1), IL-6, 
which also drive persistent inflammation and joint destruction (229, 297). 
Consequences of acute and chronic inflammation in RA have a great impact on 
quality of life, co-morbidities such as cardiovascular disease, and mortality. 
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1.1 CARDIOVASCULAR MORBIDITY AND MORTALITY IN RA 
In RA the mortality is higher in comparison to the general population and standardized 
mortality ratio (SMR) associated with RA ranges from 1.3 to 3.0 (366). The leading 
cause of morbidity and mortality in RA is cardiovascular disease (CVD) (355, 362) and 
the cardiovascular events occur approximately a decade earlier in patients with RA than 
in the general population (20, 91). The CVD-related morbidity in RA patients appears 
to be increased by two-fold or more compared to the general population (309) and is 
comparable to the magnitude of cardiovascular risk in type 2 diabetes mellitus (260). 
Increased risks are found when analyzed by incident cardiovascular events (mostly 
being caused by myocardial infarctions), causes of death, or surrogate measures of 
atherosclerosis, such as carotid artery plaque, intima-media thickness, or coronary 
artery calcification. The lower survival rate in patients with RA, mainly from 
cardiovascular disease, has not improved over time (88). Despite  milder course of RA 
disease over the past decades the magnitude of the overall CVD-dependent mortality is 
still associated with a 60% increase in risk of CVD death in RA compared with the 
general population (232). The magnitude of SMR and predictive factors appear to be 
affected by variations in study design, sample size, follow-up period, and geographic 
area. Established prevalent cohorts report SMR varying from 1.49 to 3.08 (126, 345, 
390), greater than inception and community-based cohorts, which vary from 0.87 to 1.4 
(150, 198, 215, 235, 285, 398). 
Several studies have, however, shown contradictory results, demonstrating no increase 
in either CVD or all-cause mortality during the first 10 years of RA (198, 274), thus, no 
definite conclusions on the relative CVD death rate of patients with early RA can be 
made (184, 398). The differences seen in the cohorts may be explained, at least partly, 
by the changes in treatment practices with increased and early referral to secondary 
care, earlier use of disease modifying anti-rheumatic drugs (DMARDs), especially 
methotrexate, and greater emphasis on tighter disease control. The inception cohort 
approach itself may be responsible for some of the variations reported as it allows 
inclusion of a wider spectrum of RA, and is more likely to retain patients with milder 
disease, then, generally milder RA are also usually included in community and 
primary-care cohorts (375). Retrospective studies may well be biased towards the more 
severe patients who would be more likely to be retained in the clinic setting, partly 
because of co-morbidity. 
Evidence that RA patients often die of CVD goes back over 50 years (279), the most 
comprehensive evidence comes from the recent systematic reviews of observational 
studies (17, 232). Although there is extensive data that patients with established RA 
have an increased risk of ischaemic heart disease (346), little is known about 
myocardial infarction and other organ specific CVD events in early RA. Essential 
contribution to the area has been given by the Swedish inception cohort RA study that 
reported the increased overall relative risk of myocardial infarction, 1.6 (95% CI 1.4, 
1.9), which is present already within the first 4 years of diagnosis (164). Then, in the 
incident RA cohort, the risk increase of ischaemic stroke is small and non-significant, 
overall hazard ratio (HR) 1.11 (95% CI 0.95-1.30), but the risk is heightened after 10 or 
more years since RA diagnosis, HR 2.33 (95% CI 1.25-4.34) (163). Still, the relative 
contribution of myocardial infarction and stroke to cardiovascular mortality in patients 
with RA, and whether the excess of cardiovascular risk is equal in men and women as 
well as in seropositive and seronegative RA remain unclear. 
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In addition to experiencing an increased rate of CVD events, patients with RA may 
have a worse clinical course of an acute CVD compared with patients without RA by 
presenting an excess risk of fatal CVD events (204), suffering more recurrent cardiac 
events (91), and having less chance for survival after an acute myocardial infarction 
(AMI) or stroke  (231, 319, 320). Atherosclerotic disease remains under-diagnosed in 
RA due to, at least partly, an often atypical or silent presentation which may also 
offer a potential explanation for the higher fatality rates associated with AMI in RA 
and the increases seen in post AMI complication rates (223, 386). 
 
1.2 ATHEROSCLEROSIS 
Atherosclerosis is a widespread pathologic process of medium to large arteries 
characterized by gradual thickness of the intima causing decreased elasticity of the 
vascular wall which starts in childhood and often progresses while growing older. 
The blood vessels most commonly affected and of clinically relevance include the 
aorta, coronary, carotid, cerebral and peripheral arteries. The true frequency of 
atherosclerosis and associated complications is difficult, if not impossible, to 
determine because it is a predominantly asymptomatic condition. Atherosclerosis is 
responsible for CVD events when a number of lipid regulatory and inflammatory 
mechanisms within the arterial wall is disrupted leading to blood clotting and flow 
restriction to target organ. 
Atherosclerosis and CVD are believed to be attributed to traditional risk factors, such 
as family history, cigarette smoking, high blood pressure, hypercholesterolemia, 
diabetes mellitus, obesity, estrogen replacement therapy (218), as well as additional 
factors such as age, male gender, race, physical inactivity, the individual response to 
stress, excessive alcohol consumption, and low high-density lipoprotein (HDL) 
cholesterol levels (8, 252, 400). 
 
1.2.1 Pathogenesis of atherosclerosis 
In short, initiation of atherosclerosis starts with an increased permeability of the 
dysfunctional arterial endothelium, which facilitates migration of cholesterol-filled low-
density lipoprotein (LDL) particles into the vessel wall. After migration into the intimal 
layer, LDL particles undergo modification and oxidation, inducing the endothelial cells 
to express leukocyte adhesion molecules and initiating an inflammatory response in the 
artery wall with attraction of monocytes to the lesion (315). Once in the sub-endothelial 
space, monocytes are transformed to macrophages, and subsequent incorporation of 
oxidized LDL via endocytosis by scavenger receptors differentiates them further into 
foam cells. Foam cells eventually precipitate in the vessel wall causing fatty streaks, the 
earliest recognizable lesion of atherosclerosis, which further stimulates the 
inflammatory process. Further attraction of macrophages is promoted, together with 
migration of proliferating smooth muscle cells (SMC) from the medial into the intimal 
layer of the arterial wall. SMCs produce collagen, which results in formation of a 
fibrous cap overlying the atheroma and covering the atherosclerotic plaque (213, 214). 
Recent data support the assumption that atherosclerosis is an inflammatory 
autoimmune disease (160, 288, 309). In RA, IL-1, tumor necrosis factor-alpha 
(TNF−α), and other inflammatory cytokines produced in the joints, spill into the 
circulation, where they can up-regulate adhesion molecules and other pro-inflammatory 
ligands leading to leukocyte chemotaxis into vessel walls (43). C-reactive protein 
(CRP), which increases in periods of high rheumatoid inflammatory disease activity, 
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may also have a pro-atherogenic role as it stimulates macrophages to produce tissue 
factor, an important pro-coagulant found in atherosclerotic plaques. Similar cellular 
immune system abnormalities, as perturbation of the T-cell repertoire with the 
emergence of CD4(+)CD28(null) T-cells, have been described in RA and unstable 
angina (216). Thus, immune-pathogenic mechanisms may link atherosclerosis to joint 
damage in RA, and the inflammatory process in atheromatous plaques may bear some 
resemblance to synovial inflammation of RA.  
There are two different approaches explaining the interplay between RA and CVD. 
On the one hand, RA plays an important part in modulating the risk of CVD events, 
which accumulates during the RA disease course due to RA-specific factors such as 
immune dysregulation, systemic inflammation or treatment with oral glucocorticoids 
or non-steroidal anti-inflammatory drugs (NSAIDs) (184). On the other hand, RA and 
CVD share risk factors such as genes, smoking and physical inactivity, and also, 
traditional and RA disease related CVD risk factors seem to act synergistically in 
accelerating atherosclerosis in early RA (79). There is evidence concordant with both 
of these theories, suggesting a combination of different modes of interaction (24, 108, 
350). 
Inflammation is important in the early vascular lesion that initiates plaque formation 
and growth, and also plays a role in the plaque ulceration that triggers thrombosis, thus, 
elevations in CRP and other inflammatory markers could be secondary to endothelial 
inflammation. It is also possible that inflammatory processes arising outside the 
vascular endothelium could act remotely to promote atherosclerosis (78). Underlining 
the pathogenic importance, CRP is proposed as both a marker and a mediator of 
cardiovascular disease (211, 284). However, since inflammatory activity in apparently 
healthy individuals is probably related to inflamed atherosclerotic vessels or established 
CVD risk factors, the suppression of inflammation in these patients might not be 
equivalent to suppressing disease activity in RA. Nonetheless, successful suppression 
of RA disease activity through anti-rheumatic treatments may change conventional risk 
factors and reduce CVD risk in RA (237, 294, 307, 335). 
Of note, etiology is the most difficult issue to understand in autoimmunity as chronic 
inflammation is associated with most, if not all, of traditional CVD risk factors, and 
the interplay of various factors is complex, then, it remains unclear whether 
inflammation per se is the cause or the effect of other pathogenic processes. Also, the 
pathogenesis of atherosclerosis associated with autoimmune disease may differ in 
various inflammatory phenotype and genotype settings. It is possible, that a different 
set of risk factors contribute to early-onset CVD in RA compared to late-onset CVD, 
as well as in early compared to established RA disease. 
 
1.2.2 Risk factors of atherosclerosis in RA 
Growing evidence shows that atherosclerosis cannot be fully explained by 
conventional cardiovascular factors alone (159), and CVD morbidity and mortality in 
RA occur at rates greater than would be expected from the profile of established CVD 
risk factors (83). The Framingham risk score are thought to account overall for 50% 
of CVD events in general population (281). As to patients with RA, commonly used 
prediction models are insufficient for the estimation of CVD risk. Thus, the 
Framingham risk score can substantially underestimate CVD risk in patients with RA 
in both genders, especially in older ages, and in patients with positive rheumatoid 
factor or persistently elevated erythrocyte sedimentation rates (ESR); and the 
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Reynolds risk score, which include CRP, has similar deficits in CVD risk prediction 
(63). 
Also, traditional risk factors seem to have different impact on risk for CVD events in 
RA and non-RA subjects. Age and male gender are the strongest contributors to the 
extent of atherosclerosis in the general population (151) and in RA (79). Age has a 
similar impact on CVD risk in patients with RA compared with non-RA subjects, but 
male gender and personal cardiac history appears to have a weaker association with 
CVD events in RA (145). The effect of smoking on CVD in the population is 
overwhelmingly evident, and this effect interacts synergistically with other CVD risk 
factors as age, gender, hypertension and diabetes (151). The effect of smoking (vs. 
non-smoking) is less in RA patients compared to control subjects, hazard ratios for 
CVD 1.3 and 2.2 respectively, but still, smoking is an important and modifiable 
augmenting factor for subclinical atherosclerosis in RA (136, 145). Smoking history 
is common in RA, and whilst it does not seem to confer the same relative risk of 
CVD events when compared to the general population, cigarette smoking certainly 
associates with more severe RA and also, with RF-positive or ACPA-positive status; 
both these factors independently associate with higher subclinical atherosclerosis and 
CVD mortality (135, 148, 219). In addition, dyslipidemia, hypertension, metabolic 
syndrome and obesity are highly prevalent in RA affecting about 60%, 70%, 40%, 
and 25% of patients, respectively (66, 84, 180, 253, 334). 
 
1.2.3 Carotid atherosclerosis in RA 
A diagnostic tool to detect premature atherosclerosis is carotid ultrasound, which is a 
non-invasive, simple, widely available, relatively inexpensive method assessing 
structural changes in the arterial wall. Carotid intima-media thickness (cIMT) of the 
common carotid artery, determined by ultrasound, is a useful surrogate indicator of an 
early subclinical stage of macro-vascular atherosclerosis disease (313). cIMT is also a 
strong indicator of future CVD events in otherwise healthy individuals and can 
improve coronary risk prediction beyond traditional risk factors (220, 242), 
particularly in subjects with low-grade inflammation as assessed by CRP levels (44). 
It is known that ultrasound and histological images of the cIMT are highly correlated 
(257). Moreover, carotid and coronary atherosclerosis are highly correlated as well 
(399), but this correlation does not imply that carotid cIMT is a predictor of the 
severity and extent of coronary atherosclerosis. However, carotid cIMT may perform 
as a marker of atherosclerosis in other vascular beds (74), and cIMT mean ≥ 1 mm is 
considered to be a reliable indicator of generalized atherosclerosis associated with 
increased risk of coronary heart disease in asymptomatic individuals, independent of 
major CVD risk factors (47). A systematic review and meta-analysis has shown that 
for an absolute cIMT difference of 0.1 mm the future risk of AMI increases by 10% 
to 15%, and the stroke risk increases by 13% to 18% (220). 
However, the accuracy of cIMT as a marker of atherosclerosis has been questioned by 
the fact that main predictors of medial hypertrophy or intimal thickening of the 
common carotid artery are age and hypertension, which do not necessarily reflect the 
atherosclerotic process, and normal cIMT values should be defined on the basis of 
age, sex, ethnicity, body size, and muscularity (336). Studies of the pathology 
indicate that cIMT mainly represents hypertensive medial hypertrophy or thickening 
of smooth muscles in the media, whereas atherosclerosis is largely an intimal process. 
Age-related thickening of intimal and medial layers of the common carotid also 
occurs in the absence of overt atherosclerosis (115). In contrast, carotid plaques 
probably represent a later stage of atherogenesis related to inflammation, endothelial 
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dysfunction, oxidative stress, and smooth muscle cell proliferation. Thus, it has been 
hypothesized that carotid plaque is a distinctive phenotype of atherosclerosis, not a 
simple continuum of cIMT progression (332). The review of prospective 
epidemiological data in the general population has come to conclusions that cIMT is 
an independent but relatively modest (as judged by absolute risk) predictor of 
coronary heart diseases (CHD). Then, ultrasonography-assessed carotid plaque is 
superior to cIMT for CHD prediction (168, 312). 
The accelerated and premature burden of atherosclerosis in patients with rheumatic 
diseases has been reported (80, 366), but the evidence is still not definitive (191) as 
most of the performed studies have been cross-sectional in design and with small 
sample sizes. It has been questioned whether the studies did indeed provide evidence 
for accelerated atherosclerosis in RA or reflected alternative processes, where in 
conditions of high-grade inflammation increases in carotid measures simply reflects 
current, potentially reversible inflammation of the vessel wall rather than more 
permanent structural vessel changes. Thus, a single measurement of cIMT in this 
context could not be a good predictor of future CVD events (378). 
Nevertheless, cIMT has been found to be increased already as early as within 12 
months of symptom onset of RA (158). In a recent meta-analysis it was demonstrated 
that cIMT is significantly increased in patients with rheumatic diseases, an overall 
mean difference of 0.055 mm (95% CI, 0.048-0.063) compared with healthy controls 
adjusted for age, sex and disease duration, which can be estimated to be a 7- to 8-year 
increase in age, with pre-existing CVD excluded (358). As inflammation is present 
even in the quiescent stages of RA disease, a cIMT increase per unit of age in 
proportion to RA duration has been estimated as 0.154 mm/10 years among patients 
with RA for not more than 7 years, to 0.295 mm/10 years among patients with RA for 
at least 20 years (80). When considering the presence of plaque, a significant 
difference between patients and controls has been also reported (358).  
Whether the chronic inflammatory milieu in RA disease may confound 
ultrasonography findings is unclear to date. Nevertheless, it has been supported that 
cIMT measures may be used as a predictor of CVD regardless of the absence of 
classic cardiovascular risk factors, and subjects with cIMT >0.91 mm had a high risk 
of suffering CVD events in the following 5 years, while those with cIMT <0.77 mm 
had none CVD (142). Also, it has been shown that carotid plaque presence was 
predictive for acute coronary syndrome in RA (104). Still, the meta-analysis of 
carotid measures in heterogeneous rheumatic populations has not shown agreement 
between cIMT and carotid plaque measurements (358). Taking into account 
differences in the amount and type of inflammation in rheumatic diseases, detection 
of carotid plaques by ultrasonography, not cIMT, may be a more reliable predictor of 
CVD events in patients with RA, and plaques could probably be expected potentially 
more inflammatory active, and thus, rupture-prone (292). 
Few reports are available addressing association between RA disease characteristics 
(mainly disease duration) and carotid atherosclerosis (77, 137, 143, 178, 199, 361), 
and fewer have addressed progression of carotid atherosclerosis (11, 113, 137, 141, 
318, 401), and further association of carotid atherosclerosis with future CVD events 
in early RA (104). While it could be logically presumed that anti-rheumatic 
treatments may affect carotid atherosclerosis, reports have yielded mixed results, and 
data are yet limited to biologic agents, primarily TNF-α blockers and rituximab (11, 
77, 113, 137, 141, 182, 183, 310, 391), methotrexate (113, 134, 361), and 
glucocorticoids (81, 104, 134, 137, 155, 199, 401). 
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1.2.4 Clinical atherosclerotic complications 
Etiologies of acute atherosclerotic complications have been defined as plaque rupture, 
plaque erosion and calcified nodules; and ulcerative changes, cap disruption and 
intra-plaque hemorrhage are preludes to the luminal thrombosis (384). Lipid 
accumulation, apoptosis, proteolysis, thrombosis and angiogenesis have been shown 
to be involved in the progression of the atherosclerotic lesions and plaque 
vulnerability (157). It must be emphasized that the precise mechanisms behind plaque 
progression are not understood, and that not all vulnerable plaques are likely to 
progress to rupture (195), which limits the positive predictive value of plaque 
imaging for CVD events and identifying the patient at risk. 
Morphologically, intact thin fibrous cap less infiltrated by macrophages, smaller 
necrotic core size, positive remodeling/healing, and less degree of calcification are 
features of stable plaques. Repeated intra-plaque hemorrhage, necrotic core 
expansion, changes in lipid composition of plaques, hypoxic environment created by 
increased lesion burden and inflammatory macrophages, defective clearance of 
apoptotic cells, decreased collagen fiber production, few smooth muscle cells and 
weakened thinner fibrous cap, angiogenesis, adventitial inflammation, and outward 
remodelling may precipitate plaque rupture (116, 125).  
In an autopsy study of cases of sudden coronary death, 55% to 60% of the subjects 
had underlying plaque rupture as the etiology, whereas for 30% to 35% - erosion, and 
for 2% to 7% thrombi were attributed to calcified nodules (116). Interestingly, up to 
75% of the cases of acute myocardial infarction (AMI) may be ascribed to plaque 
rupture, at the same time approximately 37% of the women with AMI had plaque 
erosion but only 18% of the men (13). Overall, the etiology of luminal thrombus is 
dependent on age and sex, where plaque rupture is a dominant mechanism in men 
regardless of age and in postmenopausal women older than 50 years, then, plaque 
erosion appears to be the primary cause of thrombus in women aged <50 years (38).  
Furthermore, arterial calcification, a regulated process similar to bone formation, 
frequently coexists with atherosclerosis, and approximately 15% of the carotid artery 
plaques contain calcifications (167). However, histopathology studies indicate that 
patients with extensive calcification of the carotid plaques are less likely to have 
symptomatic CVD disease, thus, it has been suggested that plaques calcification may 
be a plaque-stabilizing factor and protective (167). In contrast, the vulnerable plaques 
tend to be uncalcified or “mixed”. 
Vulnerable plaques tend to occur at multiple sites, and several authors have advocated 
the concept of the vulnerable patient, defined by high atherosclerotic burden, 
vulnerable plaques, or pro-thrombotic coagulation state (116). Thus, detection of 
rupture-prone vulnerable plaques is crucial in prevention. Modern vascular imaging, 
such as fluorescence imaging, MRI, CT-angiography, optical coherence tomography 
etc., improves definition of high-risk lesion in the clinic, yet, no existing diagnostic 
modality can certainly identify these lesions. To date, specific treatment approaches 
targeting unstable lesions are not known. 
Despite the clinical relevance of the mechanisms of progression of artery lesion in 
atherosclerosis and great interest for plaque stability in modern cardiology, as 
aforementioned, research addressing this question in rheumatic diseases is in its cradle. 
It seems possible that the mechanisms of atherogenesis, plaque formation, plaque 
rupture and atherothrombosis differ in RA and non-RA populations. Local and 
systemic inflammation are integral parts of plaque advancing and destabilization, 
however, in non-rheumatic individuals inflammation constitutes only 2% to 5% of total 
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lesion volume (106), whereas in rheumatic disorder the contribution of inflammation 
may be expected more significant. This is supported in an autopsy study with 
histological evaluation of coronary arteries, where patients with RA compared to non-
RA controls had less histological evidence of atherosclerosis but greater evidence of 
inflammation, more vulnerable and inflamed high-risk plaques with similar trends for 
subjects with heart failure (16). Overall, no significant difference in grade of stenosis or 
number of acute coronary lesions was found, but among subjects with CVD, 54% of 
non-RA controls had grade 3-4 lesions in left main artery versus only 7% of patients 
with RA (16). Then, in analysis of atheromatous plaques in RA patients without overt 
CVD, disease activity was associated with carotid plaque vulnerability, not cIMT 
measurement or plaque presence per se (333). 
 
1.3 LIPIDS IN ATHEROSCLEROSIS AND RA 
It has been postulated that among traditional risk factors disorders in lipid metabolism 
are central to the development of atherosclerosis, which were described already in 
1976 by Ross (289). The progress of atherosclerosis is a complex process, in which 
bi-directional interaction between lipids and inflammation is fundamental to all its 
stages (210). Healthy endothelium exerts a number of vasoprotective effects such as 
vasodilation, suppression of smooth muscle cell growth and inhibition of 
inflammatory responses, thereby helping to protect against atherosclerosis. Multiple 
lipid abnormalities, likewise systemic inflammation, may disrupt endothelial 
homeostasis. 
As dyslipidemia has been found already prior to a diagnosis of RA (239), the concept 
of dyslipidemia as an etiological factor for RA has been proposed (367). 
Dyslipidemia may be present in both early and advanced RA disease (251). In early 
untreated active RA, the lipid profile is characterized by mild dyslipidemia with low 
total cholesterol (TC), low high-density lipoprotein (HDL) and low triglycerides 
(TG). At first glance this appears to produce a less atherogenic profile, however, HDL 
levels fall disproportionately more compared to TC levels resulting in an increased 
atherogenic index (TC/HDL ratio) (59). In addition, HDL function is abnormal in 
RA, because this molecule is unable to protect LDL from oxidation; such altered 
HDL has been reported to associate also with active disease (49).  
The studies on pattern of dyslipidemia in RA are though not unanimous in conclusions. 
Some studies support a typical pro-atherogenic lipid profile in early RA, with higher 
serum levels of TC, LDL cholesterol and TG but lower serum HDL cholesterol, as well 
as smaller LDL particle size compared with controls (133, 286). In other studies, 
patients with early or advanced active RA have been characterized by relatively low 
concentrations of both TC and HDL cholesterol (33, 278).  
Lipid abnormalities seem to be linked to the systemic inflammation, at least partly 
mediated by inflammatory cytokines, such as TNF-α, with potential for a feed-back 
loop. Thus, cytokines lead to dyslipidemia that promotes oxidation, which in turn 
mediates further cytokine release at endothelial cells (110). Also, dyslipidemia in RA 
may be influenced by an array of other factors including genetic predisposition (351), 
gender, menopausal status, disease activity (55, 396), RF-positivity (55), reduced 
physical activity (99), and drug therapy (351).  
As aforementioned, associations of lipids with CVD in RA may be confounded by 
inflammation; further, lipids may have paradoxical associations with the risk of CVD in 
RA, whereby lower TC and LDL levels, and even lower atherogenic ratios (TC/HDL 
and LDL/HDL ratios) are still associated with increased cardiovascular risk (240). 
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Albeit the superiority of apolipoproteins in predicting CVD remains an area of 
debate, the mounting evidence addresses the importance of apolipoproteins as 
powerful lipid-related [e.g., apolipoprotein A1 (apoA1) with HDL, and 
apolipoprotein B (apoB) with LDL] indicators of CVD risk and important treatment 
targets in the general population (363-365). It has been postulated that apoA1 
possesses both anti-inflammatory and anti-oxidative effects. In conformity with this 
hypothesis, infusions of apoA1 or HDL to humans and animals resulted in reduced 
inflammation and atherosclerosis (249, 273). Besides, it has been shown that apoA1, 
in combination with lipid-lowering drugs, significantly reduced clinical disease 
activity and progress of erosions, as well as improved the anti-inflammatory 
properties of HDL in collagen-induced arthritis, thus demonstrating a dual therapeutic 
potential in autoimmune diseases (48). In patients with RA apoA1 and apoB  
correlate significantly with HDL-cholesterol and TC, respectively (278). ApoA1 
levels decrease in active RA (55, 134, 256, 396), mirroring the suppression in HDL. 
Also apoB levels have also been reported to be reduced at high levels of inflammation 
(130), but to a lesser degree than apoA1 (130, 256, 396).  
The use of lipid ratios (TC/HDL and LDL/HDL) and apolipoprotein ratio (apoB/apoA1 
ratio) is gaining popularity as the ratios have been shown to confer a greater predictive 
value of first CVD event and probably a better target for lipid-lowering therapy than 
individual lipid levels in the general population (112, 363). Still, it is not proved if a 
ratio change caused by an increase in apoA1 is equivalent to that caused by a reduction 
in apoB. All three lipid ratios have been reported to increase in active RA (93, 256, 
396). To use lipid ratios has been considered  attractive for risk stratification in RA as 
they may overcome effects of inflammation on individual lipid levels (59, 262, 349), 
however, other authors could not confirm this conclusion (240). 
In RA, dyslipidaemia combined with enhanced activity of pro-inflammatory 
cytokines in chronic inflammatory milieu lead to a pro-oxidative state (177), which 
further promote oxidative modification of LDL to the highly atherogenic oxidized 
LDL (oxLDL), both within the synovial fluid and the plasma of RA patients (173). 
oxLDL is likely to be of great importance in atherosclerosis and constitutes a major 
part of early vascular atherosclerotic lesions. It exhibits enhanced pro-atherogenic 
properties, through its ability to more readily infiltrate the arterial wall, to form foam 
cells and to initiate a localized inflammatory response (293). Biological actions and 
consequences of oxLDL include activation of monocytes, endothelial cells, T-cells 
and B-cells (29, 124), injuring endothelial cells, expressing adhesion molecules, 
recruiting leukocytes and retaining them (174). Further, oxLDL contains other 
oxidized products, including platelet activating factor (PAF) -like lipids (123, 124), 
and its pro-inflammatory, immunogenic and pro-thrombotic properties are probably 
mediated through the PAF-receptor, to which phosphorylcholine (PC) is the major 
ligand (12). Also, oxLDL triggers the CD40/CD40L signaling pathway through 
LOX-1, an oxidized endothelial receptor, which might also lead to a pro-
inflammatory reaction and induce endothelial injury (205). 
In the general population, increasing plasma oxLDL levels have been associated with 
a gradually increasing risk for CVD events (170, 343), and high titers of oxLDL have 
been detected in patients with AMI (96, 353). Further, the plasma oxLDL level has 
been described as the strongest predictor of CVD events compared with a 
conventional lipid profile and other traditional risk factors (230). It has been 
suggested that elevated oxLDL can play a role in the transformation from stable to 
vulnerable unstable plaque (186). Also, increased levels of antibodies against oxLDL 
have been found in patients with an early-onset peripheral vascular disease (27). 
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In RA, studies investigating the possible contribution of elevated oxLDL or 
antibodies against oxLDL to carotid atherosclerosis and CVD outcomes are limited, 
and the results are contradictory (65, 114, 259, 308, 359, 392). However, there are 
reports showing that serum oxLDL and antibodies against oxLDL are raised and 
correlate with disease activity, independently of other inflammatory markers, 
suggesting the importance of oxLDL in a chronic inflammatory condition per se (65, 
187, 259, 393).  Further studies are warranted to determine the relationship between 
oxLDL and inflammation, and the potential predictive role of oxLDL for accelerated 
atherosclerosis and CVD in RA. 
Anti-rheumatic medications alter the lipid profile with the most widely reported 
changes, at least short-term, being elevation in HDL or apoA1 levels, but also, 
increase in TC and LDL levels, without an overall change in the atherogenic indexes. 
The most likely mechanism to account for such changes in the lipid profile is 
suppression of inflammation potentially reflecting a reversal of the previously 
inflammatory-mediated suppression of the lipid profile. Interestingly, some 
medications have been shown to exert drug specific effects on the lipid profile, for 
example, hydroxychloroquine has been reported to produce a less atherogenic lipid 
profile by lowering TC, LDL and TG, and increasing HDL levels (237, 238, 282), 
while a pro-atherogenic pattern has been demonstrated in the studies evaluating 
treatment with tocilizumab (103, 132, 175, 181, 246, 247, 317). However, for other 
agents there are contradictory evidences on the impact of the drugs on lipid levels. 
Thus, for methotrexate both improved, mostly unchanged and impaired lipid profile 
have been reported (133, 255, 282, 291), as for glucocorticoids (33, 131, 133, 155, 
255, 282), TNF-α blockade (7, 35, 64, 68, 69, 129, 188, 261, 268-271, 291, 295, 328, 
331, 347, 373, 382, 385), and rituximab (144, 182). Generally, the conclusions of the 
studies are limited by small sample sizes, diversity in patient selection, different 
approaches used to adjust for disease activity, cross-sectional or non-randomized 
design (with exception for several studies of tocilizumab), various dosage of drugs 
used, different observation periods and concomitant use of other DMARDs. 
The understanding of dyslipidemia in RA remains far from complete. An overall net 
effect of suppressing inflammation may be more important for CVD risk reduction 
than the effects on lipid profiles. Still, improving RA disease per se does not seem 
enough to treat the accompanying dyslipidemias, and in CVD prevention 
dyslipidemia in RA should be managed as in the general population (258). 
Interestingly, hitherto, comparable lipid-lowering effect has been reported in patients 
with RA and those without RA, despite lower baseline cholesterol levels in RA 
patients (301, 303), and also, discontinuation of statin therapy in patients with RA for 
more than 3 months has been shown to associate with increased risk of myocardial 
infarction (76). 
Numerous challenges remain to establish the relative contribution of dyslipidemia to 
CVD in RA. Further studies are required to investigate the changes in lipid structure 
and function, the mechanisms behind beneficial or adverse effects of drugs on lipid 
profile, and more intricate effects of drugs on lipids, such as lipid subfractions, lipid 
modifications, LDL oxidation, and the impact of these changes, probably drug-
specific, on CVD risk. 
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1.4 NATURAL ANTIBODIES IN ATHEROSCLEROSIS AND 
INFLAMMATION 
The existence of B-cells subsets has not been clearly established in humans. In mice, 
distinct B-cell types have been described, B1-cells, producers of natural antibodies, 
B2-cells, which require T-cell interaction for activation and production of antibodies, 
and B10-cells, which are negative regulators of inflammatory immune response. B1-
cells spontaneously and continuously secrete antibodies, reacting with microbial 
polysaccharide and lipids, and it is possible that microbial flora in the gut are the 
source of antigens that stimulate production of these antibodies in the peritoneum. 
These self-binding, highly cross-reactive, low-affinity, non-mutated antibodies make 
up a considerable amount of the circulating IgM in humans and are referred to as 
natural or background antibodies because they occur at low abundance independently 
of antigen stimulation, and provide a non-adaptive T-cell independent first line of 
defence against pathogens (32, 92).  The natural IgM antibodies can be switched to 
IgG, without B-cell antigen receptor stimulation, in response to pathogen-associated 
molecular factors such as bacterial wall components. At birth, humans already have 
substantial levels of circulating IgM antibodies, which reflect a functional neonatal B-
cell compartment ready to contribute to neonatal host defense (311).  
Phosphorylcholine (PC) is a component of phospolipids and exists in LDL cholesterol 
and plasma membranes. The specificity of the protective autoantibodies is skewed 
towards phospholipid moieties. Natural antibodies against PC, anti-PC, can react to 
PC on bacteria, oxLDL and apoptotic cells, but not to those on unoxidized 
phospholipids, native LDL and viable cells, thus, they have a role in maintaining the 
homeostasis of the immune system (305). Most humans have a substantial immune 
response to PC and natural PC-specific antibodies (anti-PC) have been reported to 
constitute between 5-10% of the total IgM pool (248). Natural IgM antibodies possess 
a high overall binding avidity, a feature that makes these antibodies particularly 
effective in binding antigens with a repetitive structure on the surface of cells, tissues, 
bacteria and viruses. Since they also recognize a variety of self-antigens, they bind to 
a number of self or foreign antigens, e.g. nucleic acids, phospholipids, erythrocytes, 
serum proteins, and cellular components, and thus, anti-PC serve in the clearance of 
pro-inflammatory agents, apoptotic cells and released auto-antigens exposed during 
stress, tissue damage and inflammation (101). Thus, it has been suggested that anti-
PC IgM has a housekeeping role of a clearance system for aging and/or oxidized or 
otherwise modified lipoproteins and dying cells (58); if so, a high level of anti-PC is 
beneficial, while a low level may predispose for chronic autoimmune inflammation 
and atherosclerosis (306). The beneficial effects of anti-PC antibodies have been 
demonstrated both in vitro (53, 57, 73, 306), and in vivo (31, 39, 107). 
Many of the biological effects of oxLDL are exerted through platelet activating factor 
(PAF)-like lipids and lysophosphatidylcholine (LPC) (227, 341). Both agents are 
generated in the oxidation of the omnipresent phospholipid, phosphatidylcholine, 
which is abundant in LDL and plasma membranes (56, 226). This group of pro-
inflammatory/cytotoxic compounds generated in the oxidation of LDL exhibits the 
PC epitope, and PC is one of the key epitopes found on oxLDL but not native LDL 
(28, 306). Anti-PC extracted from human serum has been demonstrated to inhibit the 
pro-inflammatory effect of PAF, a potent phospholipid activator involved in changes 
to vascular permeability, lipid oxidation, chemotaxis of leukocytes, and believed to be 
major inflammatory mediators in the atherosclerotic plaque (340). Further, anti-PC 
may inhibit uptake of pro-atherogenic oxLDL in macrophages by scavenger receptors 
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such as CD36, thus, anti-PC may prevent the formation of foam cells (73) and 
clearance of atherosclerotic plaques (36). Additionally, anti-PC has been shown to 
inhibit L-α-LPC-induced death of immune cells (119), and considering the richness of 
LPC in plaques, this mechanism may be important in plaque stabilization.  
Several recent studies have indicated that deficiency of anti-PC of IgM subclass could 
play a role in atherogenesis and chronic inflammation. Low levels of anti-PC have 
independently predicted CVD in general; moreover, a negative association between 
anti-PC levels and the development of human atherosclerosis was proposed (122). 
Further, low levels of anti-PC associate with the development of ischemic stroke and 
increased risk for AMI, and could be an indicator for subsequent CVD, particularly in 
men (73, 118, 154, 314). In contrast, high anti-PC levels may be protective and 
associate with reduced rate of atherosclerosis progression, independent of known 
CVD risk factors (119, 339).  
Regarding properties of anti-PC in chronic autoimmune condition, two cross-
sectional studies in systemic lupus erythematosus (SLE), have demonstrated 
association of low anti-PC IgM levels with both carotid plaque occurrence and 
disease activity, then, low levels of anti-PC IgM were more common in SLE patients 
than in age- and sex-matched population-based controls (9, 340). The knowledge 
about levels and effects of anti-PC in autoimmune diseases and theirs value for CVD 
prediction is otherwise limited. 
The understanding of the anti-PC phenomenon remains a challenge for the future. It is 
particularly important to continue the search for novel therapeutic concepts blocking 
disease-promoting immune processes. Modulation of the immune response using 
vaccines against PC represents a potential therapeutic strategy in the management of 
atherosclerotic disease. There is a clear need for the development of innovative and 
sensitive diagnostic approaches, and anti-PC may be an interesting such an indicator 
of deficiency of immune state and a prognostic marker of efficacy of anti-
inflammatory drugs. Combining mechanistic findings made in the experimental 
systems with evaluation of biomarkers of pathological reactions of innate immune 
systems deserve further evaluation in larger cohorts to make it possible to achieve the 
aims of predictive, preventive and personalized medicine. 
 
1.5 RA DISEASE FACTORS AND CARDIOVASCULAR OUTCOMES 
In RA, the balance between pro- and anti-inflammatory cytokines is tilted toward 
continued inflammation. The normally low levels of pro-inflammatory cytokines 
become chronically increased both in serum and synovial fluid causing prolonged 
inflammation (337). Evidence suggests that the sooner the RA patients are treated, the 
better is prognosis. The availability of markers that could help to identify patients 
with more aggressive, rapidly progressive RA with poorer prognosis would offer a 
rational basis for early and aggressive treatment. In that way it may be possible to 
avoid many irreversible clinical complications. 
For many years, clinical researchers have collected observational data on small and 
large patient cohorts in order to identify those characteristics that best predict clinical 
outcome. These studies are highly diverse in almost every respect, such as design (for 
example, retrospective as opposed to prospective), the definition of the status of the 
disease, disease duration, number of patients included, length of follow-up, 
definitions of outcome variables, means to assess outcomes, baseline characteristics 
of the patients (for example, ethnicity, age, sex, smoking habits or social status), 
medication allowed before and during the study period, management of the patients 
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and intensity of intervention (316). This diversity makes a broad comparison of the 
results of various studies very difficult, if not impossible. Nevertheless, from the 
findings of many studies, several biological markers indicative of active inflammation 
seem to be dependable surrogate markers of worse clinical outcomes. 
Here, it will be discussed key questions of some serological, immunological, clinical 
and functional markers in association with risk for CVD and mortality in the context 
of RA. The predictive value of all of these markers has been challenged in several 
studies, and none has been established as the single most reliable CVD prognostic 
factor in clinical practice. It should be noticed that in relation to a comprehensive 
research on CVD and mortality outcome in RA, reports on predictive value of 
inflammatory markers in this context are sparse. 
 
1.5.1 Markers of inflammatory activity 
Erythrocyte sedimentation rate (ESR) together with C-reactive protein (CRP) is the 
most frequently used laboratory measure reflecting disease activity. CRP is the most 
extensively studied systemic marker of inflammation, an acute-phase protein 
featuring a homopentameric structure and Ca+2-binding specificity for 
phosphocholine. CRP has an important immune-modulatory role, either activating or 
inhibiting the inflammatory responses depending on the biological context, such as 
activation of complement, anti-tumor effect, binding of LDL, modulation of 
superoxide and nitric oxide release, binding to phagocytic cells, blockade of 
activation of macrophages, increased synthesis of IL-1R antagonist, inhibition of 
leukocyte adhesion to endothelial cells, pro-coagulation and opsonization of bacterial 
cell fragments (86). Most functions of CRP are easily understood in the context of the 
body’s defenses against infective agents. However, at the moment, neither the 
physiological functions of human CRP nor its possible role in disease is well known 
(86). CRP is considered to be a more specific biomarker for RA disease activity than 
ESR, since the hepatic production of CRP reflects the effects of inflammatory 
cytokines IL-1, IL-6 and IL-17 in the liver, although extra-hepatic production can also 
contribute to systemic concentrations (98). Interestingly, CRP reflects more short-
term changes in disease activity compared with ESR, which reflects disease activity 
of the previous weeks (371), thus, the timing of measurement may have important 
implications for the results of the studies. 
In an otherwise healthy population, elevated CRP levels are associated, though 
relatively modestly, with an increased risk of CVD events (71, 283). The biologic 
explanation of this association is likely due to chronic low-level inflammation in the 
vascular intima. Although elevated CRP is present in atherosclerosis it seems not 
directly responsible for it, as it is also associated with other factors which are 
themselves coupled with CVD and mortality risk, e.g., socioeconomic and lifestyle 
factors, such as smoking and BMI, and the CRP genotype (86). Thus, elevated CRP 
(383), as also ESR and other inflammatory variables, is likely a nonspecific indicator 
of more general illness and, thus, CVD, but not a specific indicator of vascular 
disease. 
The question of the comparative usefulness of the ESR and CRP in the assessment of 
RA activity has been addressed in the study by Wolfe et al. in which complete 
rheumatologic examinations and laboratory tests were assessed (visual analog scale 
pain and global severity, joint count, functional disability, depression, a composite 
measure of disease activity, ESR, CRP, hemoglobin, RF, immunoglobulins, 
haptoglobin, alpha 1-antitrypsin and albumin). The average correlation with the 
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clinical variables was similar for ESR and CRP, but a substantial portion of the 
correlation with ESR was explained by the immunoglobulins, RF, and hemoglobin 
rather than the acute phase response. Still, because ESR is sensitive to 
immunoglobulins and RF, it may measure general severity better than CRP, even 
though it is a poorer measure of inflammation (387). These data, thus, have implied 
that the combination of ESR and CRP yields useful information that is often not 
apparent when only a single test is used. 
In patients with RA, CRP and/or ESR can predict atherosclerosis measured by cIMT 
and/or the presence of carotid plaque (82, 140, 158, 254), but in other studies this 
association was not confirmed (80, 104, 176, 199). Then, women with RA and SLE, 
without prior history of diabetes or CVD,  have been reported to have a significantly 
increased odds of having coronary artery calcium (CAC) and more extensive CAC, 
detected by electron-beam computed tomography, compared with matched healthy 
controls, which was explained, at least partly, by differences in CRP levels (179). 
The association of inflammatory indicators in RA with risk of CVD morbidity and 
mortality has been explored in several studies. Both baseline ESR in early as well as 
established RA (34, 169, 390, 398) and elevated CRP ≥ 5 mg/l in newly onset 
inflammatory polyarthritis (149) have been shown to independently predict CVD 
death or all-cause mortality; on the contrary, other studies could not demonstrate this 
association (260, 290). In a study of RF-positive RA patients, a high last registered 
ESR before event was strongly predictive of incident CVD (360). It has also been 
found that the risk of CVD death was significantly higher among patients with early 
RA and a ESR values of  ≥ 60 mm/h on ≥ 3 occasions, hazard ratio (HR) 2.03 (95% 
CI, 1.45-2.83), controlled for traditional cardiovascular risk factors and co-
morbidities (224). Then, heart failure is preceded by an inflammatory activation as 
shown by ESR in early RA patients, free of heart failure prior to RA incidence date 
(225). Also, in established RA disease, approximately similar associations between 
the mean ESR or CRP levels and an increased risk for CVD events and CVD 
mortality have been found, underlying the importance of a chronically high 
inflammatory response for development of CVD in RA (139). Here again, it would be 
important to mention the synergistic action between inflammatory and traditional 
CVD risk factors, thus, in the recent inception RA cohort study the risk of a new 
CVD was potentiated by the combination of ESR at baseline and traditional factors 
(169). 
 
1.5.2 Serological markers 
RF (rheumatoid factor) and ACPA antibodies (anti-citrullinated protein/peptide 
antibodies) are established biomarkers used in both diagnosis and prognosis of RA, 
and their presence predicts a more aggressive, destructive disease course (117, 299, 
300). In contrast to the inflammatory variables outlined above, RF and ACPA are 
mostly stable over time, thus, these markers can be regarded as characteristic of a 
particular individual’s disease. 
RF is one of the auto-reactive natural polyclonal antibodies of predominantly IgM 
isotype reacting with the Fc portion of IgG, whose primary role is believed to be the 
first line defence against infection. Like other natural auto-reactive antibodies the 
main source of RF is considered to be the B1-cells. In healthy state, low-affinity 
polyreactive IgM RFs are probably beneficial as they help in clearance of the formed 
immune complexes (46). The “natural” low-affinity RF is produced by CD5(+) B-
cells found in healthy individuals during the course of a physiological response to 
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various viral and bacterial infections and during certain inflammatory conditions, 
malignancies and organ transplantation (2). The presence of RF may be useful and 
beneficial early in the course of a bacterial or viral infection. Interestingly, RF levels 
are higher in secondary compared with primary infections, and even higher in the sera 
of latent infected individuals suggesting that individuals with higher RF may not be 
clearing infections (244). 
In RA, RF-producing B-cells are stimulated and continuously produce RF. Such RF 
is mono-reactive, somatically mutated and has increased affinity; also, it may be 
produced by B-cells within the synovium. Large amounts of high-affinity RFs may be 
harmful by participation in a vicious cycle of autoantibody production by stimulation 
of self-lymphocytes, and/or deposition in blood vessels. The production of RF can be 
taken as indicator of severe RA disease with a striking involvement of B-cell 
activation (89). RF can be detected in 60-80% of RA patients in hospital series (51); 
the sensitivity for RF in RA varies from 19% to 53% and the variation in specificity 
is 91.7-98.6% (276). RF was included in the 1987 revised criteria for the 
classification of rheumatoid arthritis by the American Rheumatism Association 
(ARA) (14).   
Citrulline is an amino-acid that is incorporated into proteins during inflammation. 
The presence of ACPA, as RF, portends a more aggressive disease course along with 
a higher degree of systemic inflammation, and can be detected years before RA onset 
(26, 277). Its specificity is higher than RF, and reported ranges of diagnostic 
sensitivities and specificities are 39-94% and 81-100%, respectively (19). In 2007, 
ACPA antibodies were included in the European League Against Rheumatism 
(EULAR) guidelines for the diagnosis of early RA, and in the American College 
Rheumatology (ACR) criteria for RA classification (61, 209). 
There are data suggesting an association between RF and/or ACPA and risk for CVD 
and mortality in RA and also in healthy individuals. This association can partially be 
explained by cigarette smoking as smoking is associated with RF and ACPA 
production. However the heightened CVD and mortality risk does not appear to be 
linked only to smoking neither in the general population nor in patients with RA (145, 
161, 360, 362). 
In the general population, RF is an independent risk factor for ischemic heart disease, 
all-cause and/or CVD mortality, at least in men (3, 94, 348). In a population-based 
longitudinal study, participants with “false-positive RF” titers of ≥ 128 have been 
found to have a 74% increased risk of CVD deaths (161). The presence of RF, but not 
ACPA antibodies, has recently been confirmed to be a significant predictor of CVD 
events and mortality in both those with and those without rheumatic diseases, which 
supports the role of immune dysregulation in the etiology of CVD disease (207). 
In a primary care-based inception cohort of patients with inflammatory polyarthritis 
of short-disease duration, RF-positive subjects had increased rate of death from all 
causes as well as death attributed to CVD (150). Such an excess mortality has been 
confined in recent-onset arthritis in elderly (138). Additionally, in several other 
studies of patients with RA, RF-positivity has been found to predict all-cause and 
CVD mortality (50, 146, 148, 274, 390). Then, in women with RA, presence of a 
positive RF has been reported to be associated with increased mortality and relative 
risks of incident CVD events (235, 326). Here also, RF- and/or ACPA-positivity, 
among other markers of RA severity, together with traditional CVD risk factors are 
likely to contribute to prediction of CVD events in RA, and increasing frequency of 
both types of factors are associated with greater risk (327). 
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ACPA antibodies has been associated with the development of ischemic heart 
disease, odds ratio (OR) 2.8 (95% CI 1.19-6.56), and also, with higher mortality rates, 
OR 1.72 (95% CI 1.01-2.91) (219). The excess risk of premature death seems to be 
most marked for patients with inflammatory polyarthritis and RA in conjunction with 
ACPA, smoking history, and the HLA-DRB1*01/*04 gene (108).  
Strikingly few studies have examined the relationship between serological markers 
and findings of subclinical atherosclerosis, but the results of one study does imply 
that patients with RA who are positive for ACPA have enhanced subclinical 
atherosclerosis compared to those who are not (135).  
However, there is discordance in published data addressing relationship of 
autoantibody status and atherosclerotic outcomes, with negative results reported in 
several studies (34, 80, 104, 139, 169, 260, 356). 
 
1.5.3 Measures of RA disease 
There are six core outcomes which are recommended in clinical studies of RA, i.e. 
disability, pain, the patients global assessment of general health, the physician global 
assessment of disease activity, swollen joint count and tender joint count (1). Because 
of heterogeneity of the disease, a set of variables is preferred to one single variable to 
assess disease activity (372). Currently, no gold standard measure exists for RA 
disease activity. 
 
1.5.3.1 DAS28, a composite measure of disease activity 
In daily practice and clinical trials, disease activity in RA is usually measured by the 
composite index Disease Activity Score 28 (DAS28), consisting of a 28 swollen joint 
count (range 0-28), a 28 tender joint count (range 0-28), ESR, and the patients general 
health assessment on a visual analogue scale (range 0-100) (272). The DAS28 has a 
continuous scale ranging from 0 to 9.4, and the DAS28 < 2.6 classifies as disease 
remission, the DAS28 < 3.2 as low disease activity, the DAS28 between > 3.2 and    
< 5.1 as moderate activity, and the DAS28 >5.1 as high activity (121). This score has 
been shown to correlate with other indices of inflammation and disability (272). 
When exploring utility of the DAS28, it is important to notice, that the DAS28 was 
developed and validated to evaluate disease activity status in groups of patients with 
RA participating in clinical trials to reflect a clinical meaningful target of anti-
rheumatic treatment (low disease activity), but has not been validated for use in the 
individual patient. Thus, the reliability of the DAS28 for assessing disease activity in 
individual patients has been questioned, as overestimation can arise from elevated 
ESR (due to reasons other than disease activity), or fibromyalgia (352). Another 
shortcoming of this index is a reduced sensitivity to assess low disease activity or 
remission (more false-negative cases) (201). Taking into consideration the presence 
of less objective components in the DAS28 and discordance between the DAS score 
and the physician's assessment of RA activity (389), evaluation of not only the 
DAS28 but also its individual components along with a full physical evaluation could 
be recommended. 
Evidence on the value of the DAS28 in prediction of future CVD events and mortality 
outcomes in RA is limited, but some data are available. Thus, in male veterans with 
RA, DAS28 ≥ 5.1 predicted subsequent major adverse CVD events, HR 1.3 (95% CI 
1.1-1.6), independent of traditional CVD risk factors (22). Several studies have also 
found the association between the DAS28 (as a single measure at inclusion or a 
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cumulative measure) and risk of CVD and/or mortality in RA (169, 274), while other 
studies have reported a lack of association (104, 275). 
 
1.5.3.2 HAQ, measure of physical function 
Functional assessment is commonly made using the self-reported Stanford Health 
Assessment Questionnaire (HAQ). The Swedish version scores the ability to perform 
20 daily activities grouped into 8 categories, and ranges from 0 (least disability) to 3 
(most severe disability) (97). Correlation for reliability, i.e. the ability to reproduce 
results, ranges from 0.87 to 0.99, and for validity, i.e. the degree to which it measures 
what it is intended to measure, ranges from 0.71 to 0.95 (37). The HAQ score 
correlates moderately with disease duration, joint pain, other disease activity 
measures, educational status and low socioeconomic background, as well as female 
sex and muscle strength (156, 370, 388).  
HAQ is a useful instrument for groups of patients even though individual patients 
show great variation over time, and upward reappraisal of functional ability with 
increasing time (388). As with any instrument, the HAQ score has limitations, such as 
the lack of sensitivity to small changes at the ends of the spectrum and the floor and 
“ceiling effects” (in certain circumstances, the score cannot worsen). Also, absolute 
changes in the upper range and in the lower range are probably not comparable, i.e. the 
score data are not truly continuous (37). The HAQ score is affected by both reversible 
and irreversible components of the disease process, and longstanding disease lessens the 
potential for improvements in score because of irreversible damage. Thus, patients with 
RA may derive benefits from treatment that are not reflected in the HAQ score because 
of irreversible joint damage (37). 
The HAQ score has proved to be a strong predictor of all-cause and/or CVD mortality 
(34, 40, 150, 234, 266, 390, 398), probably to the same extent in both RA and the 
general populations (322). Moreover, it has been suggested that the 1-year HAQ score 
may perform as a stronger independent predictor of mortality than the baseline HAQ 
in RA (109, 398). On the contrary, data on the role of the HAQ score for adverse 
CVD events are limited, with few reported findings of positive association for the 
HAQ scores ≥  1.38, or ≥  2 (171, 327). 
The inconsistency in reports of mortality and CVD outcomes in relation to the HAQ 
score in RA invokes the possibility that the functional score may provide indirect 
measure of the patients’ overall health status/age/co-morbidities, at least in 
established RA disease, and provide less information on cumulative inflammation.  
 
1.5.3.3 Measure of pain 
Pain can be measured by a visual analogue scale (VAS), range from 0 (none) to 100 
mm (extremely severe). A number of studies have established that data from self-
reporting visual analog scales are reproducible, and the score of 10-25 mm VAS may 
indicate normal status (321).  
A visual analog pain scale was initially used in psychology by Sigmund Freud and 
others since the early 1900s; in rheumatology, the use of a pain VAS was developed 
in the in the late 1970s (321). Pain follows the same pattern of development as other 
variables of disease activity in groups of patients with RA, after initial improvement, 
pain scores slowly deteriorate over the years. In early severe RA pain reflects the 
nociceptive effects of local inflammation and is significantly correlated with patients' 
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global health assessment, HAQ and laboratory variables (ESR, CRP) (194, 321). 
Although significant correlations can be seen between pain scores and the 
radiographic scores of small joints, the strongest associations are seen between pain 
score and the scores for functional status and the psychological constructs of anxiety, 
depression, helplessness, and lack of self-efficacy (105, 296, 321, 323). A 
quantitative assessment of pain is generally recommended to be carried out at each 
visit in routine rheumatology care, along with an assessment of functional disability, 
the global status, and other patient variables. 
Although controlling pain is one of the targets of successful treatment (379), 
unfortunately, many RA patients continue to suffer pain despite a range of treatments 
with DMARDs and symptomatic drugs (6). In the general population, pain is 
suggested to be one of the modifiable risk predictors for premature mortality (10, 
324). If pain and changes in the pain scores in the course of RA exert an effect on 
future adverse CVD outcomes and can be used for prognosis deserve investigation. 
 
1.5.3.4 Key considerations 
Prospective cohort studies including several inflammatory and RA disease related 
markers are necessary to assess the value of more complex models as predictors of 
outcomes in RA. Models involving several biomarkers and clinical markers may 
result in a biomarker signature capable of predicting and monitoring outcomes 
important to patients. In turn, this has the potential to allow tailoring of treatment 
regimens and prevention to groups of patients according to their biomarker signature 
and would truly represent personalized medicine. 
 
1.6 ANTI-RHEUMATIC THERAPIES AND CARDIOVASCULAR RISK 
There is a complicated relationship between cardiovascular conditions and 
inflammatory activity, disease severity, and drug therapies used in RA, which is not 
fully understood (21, 190). In recent years considerable attention has been drawn to 
the ability of anti-rheumatic drugs to modulate CVD and mortality risk in RA via 
specific targeting of the inflammatory process implicated in atherogenesis and 
atherothrombosis. Although results from observational studies vary (128, 197), and 
the current evidence is not definitive, there is a real possibility that better disease 
control could confer survival benefits (54, 197, 236). 
Controlling systemic inflammation may reduce risk of CVD and premature mortality, 
but therapies themselves may contribute to atherogenesis and/or mortality due to 
unfavorable effects (241). Despite frequent use of NSAIDs and also glucocorticoids 
(GCs) by patients with RA, and concerns surrounding CVD risk in association with 
their use in the general population (162, 330, 354, 376), this issue has not been 
extensively studied in patients with RA. Though some observational studies could not 
confirm NSAIDs- or corticosteroids-associated CVD risk in RA (30, 147), hitherto, 
the published data do not provide firm conclusions about benefit/harm profile of these 
drugs in a condition of a marked inflammatory burden. 
Use of any DMARDs (169, 243, 342, 362, 368), in particular methotrexate (MTX), 
and/or biologic agents  (4, 23, 54, 153, 171, 233, 380, 381), may halt CVD and 
reduce CVD mortality; this is again thought to be due to effective long-term control 
of systemic inflammation. Thus, in severe RA, non-responders to MTX treatment 
have been documented to have a poor survival prognosis with >4-fold increased 
mortality compared with the general population, while patients who respond to MTX 
had only a moderately increased mortality rate (197). Also, a risk reduction in the 
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incidence of AMI has been found in responders compared to non-responders to TNF-
α blockade (87). 
A recent meta-analysis has explored the relation of MTX therapy with CVD in 
patients with RA, psoriasis, or polyarthritis, and in observational studies the use of 
MTX was associated with a 21% lower risk for total CVD (95% CI, 0.73-0.87) and 
an 18% lower risk for AMI (95% CI, 0.71-0.96). Importantly, stronger associations 
were observed in studies that adjusted for underlying disease severity (233). 
According to a systematic literature review, the effect of anti-TNF-α agents on 
reduction of CVD in RA has not been as consistent as in studies of MTX (380). Still, 
the meta-analysis of cohort studies, but not randomized controlled trials (RCTs), has 
found that anti-TNF-α therapy was associated with a reduced risk for all CVD events, 
pooled adjusted RR 0.46 (95% CI, 0.28-0.77) (23).  
Although National Registries provide comforting data about CVD safety of anti-
TNF-α therapies (87, 217), they cannot adequately assess the actual risk, as these 
drugs are administered to patients with no cardiac dysfunction. An increased risk of 
heart failure with TNF-α blockade has been documented (200, 304).The common 
shortcomings of many studies which have investigated the impact of drugs on risk of 
CVD and mortality in RA are highly different patient populations, various inclusion 
criteria and definition of the outcomes, inadequate control for confounding factors 
and response to treatment, various total duration of therapy and cumulative drug 
exposure in conjunction in different stages of RA disease, and confounding by 
indication. However, despite limitations of the studies, the results yield some 
important, conclusive information which raises the possibility of specific 
interventions to reduce CVD morbidity and premature mortality in RA. The 
hypothesis to be tested is that tight control of disease activity would dissociate the 
inflammatory clinical variables at baseline from their predictive value, i.e. 
“dissociation of risk and reality” (316).  The EULAR recommendations highlight the 
need for rheumatologists to treat RA patients with active disease early and 
effectively, identify patients at-risk for coexistent risk factors and treat them actively 
or with preventative measures accordingly, and this applies especially to 
cardiovascular co-morbidity (258). 
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2 AIMS 
 
i. To explore whether treatment with biologic agents in patients with RA, as 
TNF-α blockade and anti-CD20 therapy influences CVD biomarkers, such as 
apolipoproteins, oxidized LDL, and the atheroprotective IgM antibodies 
against phosporylcholine (anti-PC IgM) 
 
ii. To examine the associations of established CVD risk factors, RA disease 
related factors and novel cardiovascular biomarkers, such as apolipoproteins, 
oxLDL and anti-PC IgM with measures of carotid atherosclerosis 
 
iii. To analyse whether the aforementioned novel cardiovascular biomarkers, RA 
disease factors and measures of carotid atherosclerosis are linked to incident 
CVD events during prolonged follow-up 
 
iv. To estimate the associations of disease related factors and anti-PC IgM 
antibodies the first years after diagnosis of RA with incident CVD morbidity 
and all-cause mortality, and to determine whether the impact of these factors 
differ in patient groups depending of age at onset of RA 
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3 PATIENTS AND METHODS 
3.1 PATIENTS 
The studies were of prospective observational design. At inclusion, all participants 
had a RA diagnosis according to the ACR criteria (14). Concomitant disease-
modifying anti-rheumatic drugs (DMARDs) were chosen by the treating physicians 
in accordance with the current recommended treatment strategy in Sweden, at that 
time, the strategy implied initial monotherapy with DMARDs and early use of low-
dose oral glucocorticoids, with “step-up” combination therapy reserved for more 
severe disease. 
All study participants provided written informed consent. The studies were approved 
by the Regional Ethic committee in Stockholm, Sweden, and were performed in 
accordance with the Declaration of Helsinki. 
Paper I. A total of 215 outpatients with established RA disease were identified from a 
prospective cohort of patients registered in the local database, including all patients 
treated with biologic agents at the Rheumatology Department, Karolinska University 
Hospital Huddinge. They had started their treatment with TNF-α blockade, or 
rituximab between January 2000 and October 2007, and were enrolled consecutively 
into the study in case they had remained on the treatment for at least one year, and if 
they had been biologic-naïve earlier (in case of anti-TNF-α treatment). At that time, 
rituximab was used mainly in patients that had failed on anti-TNF-α therapy, and 
68% of these patients had been taken anti-TNF-α treatment earlier. One course of 
rituximab was given during the study period. 
Of the patients, 162 had been treated with anti-TNF-α (etanercept, n=60; infliximab, 
n=60; adalimumab, n=42), and 53 with rituximab. The patients were aged 57.9 (12.4) 
years, 75% of them were females, 85.6% RF-positive, and 87% had erosive disease 
after a mean disease duration of 8.5 (5-15) years. At the time of initiation of 
biological therapy, they had a median CRP of 24 (10-46) mg/l, a mean ESR of 43 
(24) mm/h, and a mean DAS28 of 5.7 (1.1). Of the patients, 70% used concomitant 
MTX, and 45% oral glucocorticoids in dosage of 7.5 (5-10) mg daily. 
Papers II-IV. We used the study population from the early RA cohort, BARFOT 
(Better Anti-Rheumatic FarmacO-Therapy). The BARFOT is a six-centre prospective 
observational study covering both urban and rural patient’s referral areas. The 
BARFOT was designed and started in the early 90th in order to investigate clinical 
and therapeutic aspects of early RA in the long term (344). The inclusion criteria for 
the BARFOT were RA diagnosis according to the ACR definition (14), age >18 years 
and disease duration ≤ 12 months. After baseline evaluation, regular follow-up 
assessments according to the study protocol had been conducted. The BARFOT 
database is regularly updated. 
Papers II-III. In these studies, the study population was 114 patients from the 
Rheumatology Department Huddinge (one of the BARFOT’s centre), who between 
June 2000 and March 2004 had been followed for five years since RA diagnosis and 
were aged < 70 years at BARFOT inclusion. Of 203 eligible patients, 114 individuals 
were available and willing to undergo high-resolution B-mode ultra-sonography of 
the carotids. Thus, 89 subjects were not included because of unwillingness or because 
they had moved. These non-participants did not differ from the patients included in 
the study in age, sex, baseline DAS28 and functional disability. The follow-up lasted 
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5 years (paper II) and 12 (2.9) years (paper III). The main characteristics of the 
patients at the study entry are shown in the table below. 
Paper IV. The study base consisted of all BARFOT patients with early RA who were 
consecutively recruited from 1993 through 1999, n=861. Individuals with prevalent 
CVD at RA diagnosis, n=113, and patients who were < 20 years of age at inclusion, 
n=7, were excluded. The final study population consisted of the 741 patients. The 
median observation time was 13 (12-14) years. The patient’s characteristics at the 
study entry are summarized in the table. 
 
Table. Patient characteristics at time for inclusion in the studies 
 Papers II and III 
114 patients 
Paper IV 
741 patients 
Age, years 50.6 (11.2) 55.0 (14.7) 
Females, % 68 68 
Smokers, ever, % 68 59 
Diabetes mellitus, % 2 5 
Hyperlipidemia, % 2 1 
RF-positivity, % 59 60 
Disease duration, months 6 (3) 6 (3) 
CRP, mg/l 24 (11-46) 19 (6-46) 
ESR, mm/h 43 (26) 36 (26) 
DAS28 5.4 (1.2) 5.1 (1.3) 
HAQ score 1.2 (0.6) 1.0 (0.6) 
Therapies:   
methotrexate, % 19 44 
glucocorticoids, % 35 51 
 
 
3.2 METHODS 
3.2.1 Disease assessments 
Clinical and routine laboratory examinations were conducted at treatment initiation 
with biologic agents and after 3, 6 and 12 months (paper I), at inclusion to the 
BARFOT study and after 3, 6, 12, 24 and 60 months (papers II-III), and at inclusion 
to the BARFOT study and after 12 and 24 months (paper IV). Demographics, medical 
history, smoking status, anthropometric data and disease measures were obtained 
from the medical records (paper I) and the BARFOT database (papers II-IV).  
RA disease activity was calculated using the Disease Activity Score for 28 joints 
(DAS28) with ESR (272). A DAS28 < 2.6 was classified as disease remission (120) 
(paper I). Functional status was self-assessed by the validated Swedish version of the 
Stanford Health Assessment Questionnaire (HAQ), range from 0 to 3 (97). Pain was 
measured by a visual analogue scale (VAS pain), range from 0 to 100 mm. 
Information on medication, cardiovascular risk factors, the presence of co-morbid 
conditions were collected through the BARFOT registry and medical records, and 
also, through discharge diagnoses from hospital admissions, ICD-9 and ICD-10 codes 
(paper IV). At each follow-up visit information on medication was up-dated, and the 
regular use of DMARDs, biologic agents and glucocorticoids was considered if it was 
reported at least during 6 months throughout the follow-up (papers II-IV). 
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Papers II-III. At BARFOT inclusion, a patient was defined as having a pre-existing 
CVD if angina pectoris, acute myocardial infarction (AMI), coronary surgery or 
ischemic stroke were diagnosed by a physician according to current criteria and 
documented in patients’ medical history. 
Paper IV. Prevalent CVDs at RA diagnosis were tracked through medical records and 
administrative data sources, and included AMI, angina pectoris, heart failure, atrial 
fibrillation, peripheral arterial disease, ischemic stroke and transient ischemic attack. 
 
3.2.2 Assessment of traditional cardiovascular risk factors 
Smoking status was self-reported as daily ever smoking (current or past) or never 
smoking. Hypertension was considered if prescription of anti-hypertensive 
medication and/or blood pressure above 140/90 mm Hg (paper I-III) or documented 
diagnosis (paper IV). Diabetes mellitus was defined as history of diabetes and/or 
prescription of anti-diabetic medication (papers I-IV). Dyslipidaemia was defined as: 
prescription of lipid-lowering drugs (paper I) and/or serum apoA1 <1.25g/l for 
women and <1.15g/l for men, apoB ≥ 0.9g/l for both genders, apoB/apoA1 ratio ≥ 0.6 
for women and ≥ 0.7 for men (363) (paper II); total cholesterol (TC) ≥ 5.0 mmol/L, 
or low-density lipoprotein (LDL) ≥ 3.0 mmol/L (paper III);  documented diagnosis 
(paper IV). 
 
3.2.3 Laboratory assays 
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were analysed 
with routine methods. CRP was measured by a non-high sensitive assay and low 
levels were reported as < 10 mg/l. Rheumatoid factor (RF) was measured by 
agglutination test where a positive titre was > 1/20 (papers I-III).  
Venous non-fasting blood samples were also aliquoted immediately and collected for 
storage (–70°C) in a bio-bank for the following analyses. Sera at study enrolment 
were analyzed for RF IgM using the Serodia agglutination test, (Fujirebio, Tokyo, 
Japan), a titre of > 20 IU/ml was regarded as positive, and anti-citrullinated peptide 
antibody (ACPA), using the ELISA CCP2 test, (Euro-Diagnostica, Malmö, Sweden), 
positive ACPA was defined as a titre > 25 U/ml (paper IV).  
Apolipoprotein A1 (apoA1) and B (apoB) were determined with Modular Analytics 
P, Roche Diagnostics (paper I), and with Synchrone LX from Beckman AB (papers 
II-III) by immunoturbidimetry at the Study centre for laboratory medicine, Karolinska 
University Hospital, Stockholm, Sweden. The apoA1 reference intervals, given by the 
Study centre, are 1.10-2.10 g/l for women and 1.10-1.80 g/l for men. The apoB 
reference interval is 0.50-1.50 g/l for individuals younger than 40 years and 0.50-1.70 
g/l for those who are of 40 years and older.  
OxLDL (papers I-III) and anti-PC IgM determinations were carried out using a 
commercial enzyme linked immunoassay (ELISA) kit (Mercodia AB, Uppsala, 
Sweden), and Athera CVDefineTM ELISA kit (Athera Biotechnologies AB, 
Stockholm, Sweden) according to the protocols provided by the manufacturers and 
essentially as described earlier (100, 314). Coefficients of variations were < 6.2% for 
oxLDL, and < 7% for anti-PC IgM. 
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3.2.4 Carotid intima-media measurements 
Papers II-III. High-resolution B-mode ultrasonography of the carotids was performed 
approximately 5 years after RA disease onset, between June 2000 and March 2004. 
The right and left carotid arteries were examined with a duplex scanner (Aspen, 
Acuson, Mountain View, Ca, USA) using a 7 MHz linear array transducer. The far 
wall of the common carotid artery (CCA), 0.5 to 1.0 cm proximal to the beginning of 
the carotid bulb, was used for measurements of the carotid intima-media thickness 
(cIMT). The cIMT was defined as the distance between the leading edge of the 
lumen-intima echo and the leading edge of the media-adventitia echo and was 
measured in the region free of atherosclerotic plaques. For right and left CCA the 
mean values of the cIMT within the 10 mm long section were estimated. Then, the 
mean cIMT [(right + left)/2] was calculated. Carotid plaque, defined as a localized 
intima-media thickening of greater than 1 mm and at least a 100% increase in 
thickness compared with adjacent wall segments, was screened for in the common, 
internal and external carotids (203). Plaque occurrence was classified as the absence 
of plaque (none), the presence of unilateral plaque and the presence of bilateral 
plaques. The carotid measurements were made by two certified ultrasonographers.  
The intra-reader coefficient of variation for cIMT was 3.2%. 
 
3.2.5 Assessment of CVD outcomes 
Paper III. The study outcome was the first ever CVD event occurring during the 
follow-up. Information on incident CVD event was obtained retrospectively and 
validated through a structured review of the medical records. The CVD events were 
predefined as any incident acute myocardial infarction (AMI, a diagnosis based on 
history, electrocardiogram [ECG], and/or echocardiography together with typical 
enzymatic pattern and/or angiography), angina pectoris (registered as history of 
typical chest pain with compatible ECG or myocardial scintigraphy, stress ECG or 
stress echocardiography and/or angiography), congestive heart failure (CHF) (a 
recorded diagnosis based on history of at least one episode of symptomatic heart 
failure with continued dyspnoea, New York Heart Association class 2-4 together with 
typical radiography and/or echocardiography) or ischemic cerebrovascular event 
(both ischemic stroke and transient ischemic attack diagnosed with a typical clinical 
picture with neurological deficits and/or verified with computerized tomography 
and/or magnetic resonance imaging). 
Paper IV. The outcomes were a composite incident CVD event (i.e. fatal or non-fatal 
myocardial infarction, cardiac arrest, angina pectoris, coronary bypass grafting or 
percutaneous coronary intervention, peripheral arterial disease, angioplasty or other 
vascular surgery, fatal or non-fatal stroke and transient ischemic attack) and all-cause 
mortality. The observation period started between July 1993 and October 1999, i.e. 
when the patients were included in the BARFOT-study. The follow-up lasted until 
occurrence of the first-ever incident CVD event, death, or to December, 2010, 
whichever came first. Survival confirmation and date of death were obtained from the 
Swedish National Population Registry. Morbidity data was obtained from the 
Swedish Hospital Discharge Registry, between January 1987 and December 2010, 
cause of death from the National Cause of Death Registry, last updated in December, 
2010. Registry records were checked for quality of data by comparing with complete 
medical records. 
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3.2.6 Statistical analysis 
Descriptive analyses of all variables utilized in the data analyses were conducted. 
Continuous variables were summarized as mean (SD) if normally distributed, or 
median (IQR) if not. Categorical variables were presented as frequencies 
(percentages). oxLDL and anti-PC IgM levels were dichotomized by percentiles, or 
determined as continuous variables as indicated. 
Clinical features were compared, using the t-test, Mann-Whitney U-test or Wilcoxon 
rank test for continuous variables, Kruskal-Wallis test for multiple samples, and the 
chi-square or the Fisher exact tests for categorical variables. Spearman test was used 
to examine correlations. Log transformations were undertaken if required to fulfill 
assumption of normality.  
Area under the curve (AUC) using the trapezoidal rule was calculated for the core 
disease measures assessed at inclusion and after 1 and 2 years, and reduction (∆) 
between inclusion and 1 year after enrolment (paper IV). 
A 2-tailed value of p <0.05 was considered significant. All statistical analyses were 
performed using STATISTICA (Stat Soft Scandinavia AB, Tulsa, OK, USA) and 
IBM SPSS (SPSS Inc., Chicago, IL). 
Paper I. McNemar’s test was employed for dichotomous outcomes in analysis of 
differences in one sample at different time-points. To analyse longitudinal changes in 
IgM anti-PC we used repeated measures ANOVA in the complete dataset with 
probabilities for post-hoc test for between and within group comparisons at different 
time points. A multivariate approach was applied as indicated in order to elucidate the 
possible effect of intergroup differences.  
The fact of intermittent missing data of outcome variables, like anti-PC, oxLDL and 
apolipoproteins after 6 or 12 months observations (overall, 13% and 7.8% missing 
data, respectively), was a concern. Because of high variation of the primary 
objectives and skewed distribution of the variables, we chose not to use imputation 
techniques while taking into consideration reduced power of our analyses. No 
statistically significant differences were observed between patients with complete and 
missing data in regard to age, sex, history of smoking and co-morbidities, DMARDs 
and glucocorticoid treatment, usage of lipid-lowering medication and baseline 
features of RA disease activity. 
Paper II. To investigate the association between study outcomes and different risk 
factors, we applied a series of univariate regression analyses. Then, we constructed 
multivariate regression models (linear for continuous outcome and ordinal logistic 
regression for categorical outcome) to detect a combination of significant traditional 
factors, and then, to this base model we added studied factors one by one, entry 
procedure with p <0.10 criterion.  
Paper II-III. To evaluate the relationship between variables measured repeatedly over 
first five years after RA diagnosis and study outcomes, we applied mixed linear 
modeling for continuous variables and GEE (generalized estimating equations) for 
dichotomized variables with two between-group factors (plaque presence or not, 
occurrence of CVD event or not) and one within-group factor Time (0, 3, 12, 24, 60 
months). Time was modeled as a categorical variable because of unequally spaced 
time intervals. To allow for the means of the response variables to differ between 
CVD and none CVD groups as time progresses, an interaction term with factor Time 
was included in the models. The best fit model was chosen according to the 
covariance structure and the smallest value of the Likelihood Information Criteria. 
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For these longitudinal analyses, in paper III, 9 cases with CVD ahead of RA onset 
were excluded. 
Paper III-IV. The outcomes’ incidence rates (with the 95% confidence interval (CI) 
for a Poisson count) were presented as events per 100 person-years at risk, performed 
separately for the whole follow-up period and for the observation period after carotid 
ultrasonography examination (paper III), and for the study outcomes apart (paper IV). 
The Kaplan-Meier method was used to describe the outcome-free survival for the 
groups stratified by cIMT in tertiles or carotid plaque occurrence (paper III), and to 
assess the relationship between anti-PC IgM levels, dichotomized by tertiles, and the 
outcomes (paper IV). Log-rank (Mantel-Cox) statistic was applied to compare the 
survival functions obtained from the groups. 
The main analyses tested Cox proportional hazard models, with predictors of interest 
as the independent variables. Unadjusted models were tested first, followed by 
multivariate models, entry procedure with p <0.10 criterion, which were adjusted for 
age (paper III), and also for gender, smoking at enrolment, presence of hypertension, 
diabetes or hyperlipidemia (paper IV) as fixed-in-time binary variables measured up 
to the date of the outcome or the end of the follow-up (papers III-IV). Stratified 
analyses within age groups (<65 years old, ≥ 65 years old at RA onset) were also 
done (paper IV). Cases with a CVD event within five (paper III) or two (paper IV) 
years after inclusion were excluded from analyses if required for the correct 
interpretation. A 95% CI for hazard ratio (HR) was used to estimate the likely range 
of effect for the population coefficients. 
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4 RESULTS AND DISCUSSION 
4.1  APOLIPOPROTEINS AND OXLDL 
4.1.1 Influence of biologic agents 
Paper I. In established RA disease, levels of apolipoproteins did not differ 
statistically between the groups of patients ahead of treatment with anti-TNF-α or 
rituximab. The mean apoA1 was normal, >1.29g/l, but the mean apoB was elevated, 
>0.88 g/l, resulting in a high mean of pro-atherogenic apoB/apo1 ratio, >0.69, in all 
study groups. Overall, levels of apoA1 increased throughout the treatment period, and 
towards 12 months apoA1 had stabilized at higher levels than at baseline. At the end 
of follow-up, i.e. one year after commencement of biological therapy, apoA1 had 
increased, on average, by 8.5% on etanercept, by 2.3% in the total anti-TNF-α group, 
and by 6.7% on rituximab, with no significant inter-group difference. The apoB and 
the apoB/apoA1 ratio remained relatively stable throughout the whole study period. 
At baseline, oxLDL levels did not differ between the treatment groups. After 3 
months of therapy, oxLDL had increased significantly both on anti-TNF-α and 
rituximab treatments, on average, by 4% and 6% respectively, but this increase waned 
thereafter. 
Associations between changes in lipids and inflammatory markers during the period 
of follow-up were similar in patients on TNF-α blockade and those on rituximab. In 
the whole study population, a low to moderate negative association was observed 
between absolute change (∆) in apoA1 levels and ∆CRP at 6 months, r= -0.23, 
p=0.002, and at 12 months, r= -0.27, p=0.0001. Similarly, ∆oxLDL levels were 
inversely correlated with ∆CRP: at 3 months, r= -0.18, p=0.009; at 6 months, r= -
0.26, p=0.001, and at 12 months, r= -0.24, p=0.001. We did not detect any significant 
associations between the apoB, the apoB/apoA1 ratio and changes in disease activity 
during follow-up. 
The changes in the levels of apolipoproteins and oxLDL were documented during a 
period of an overall decrease in RA disease activity and similar reductions in DAS28 
in patients treated with anti-TNF-α and rituximab. 
Conclusions and discussion: Both anti-TNF-α and rituximab treatments improved 
the apoA1 levels but transiently worsened the oxLDL status. Likely, these findings 
correspond to the increased anti-atherogenic lipids but also the trend of increased pro-
atherogenic lipids, such as total cholesterol and triglycerides, in relation to improved 
inflammatory measures reported in other studies (59). Importantly, the effect on lipids 
was not agent specific but rather a result of a reduced disease activity. Consistent with 
earlier reports the magnitude of changes in apoA1 was fairly mild (268).  
The pattern of lipid levels during inflammation is pro-atherogenic and believed to 
contribute to atherosclerosis, especially in chronic inflammatory diseases such as RA. 
TNF-α inhibitors and CD20 targeted therapy can reduce disease activity and 
structural damage, and thus, could also diminish the increased CVD risk associated 
with RA by attenuating systemic inflammation linked with atherogenesis (87, 172).  
Published reports on apolipoprotein levels after short- and long-term treatment with 
anti-TNF-α in patients with RA are contradictory, and with regard to lipid changes, 
rituximab has been poorly studied (69, 268). It is uncertain, whether biologic agents 
influence lipid homeostasis by direct mechanisms or via dampening of inflammation. 
As to  TNF-α, accumulated data indicate that it could directly perturb the lipid 
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metabolism through several mechanisms, such as suppression of free fatty acid uptake 
and promotion of lipogenesis, induction of lipolysis, inhibition of lipid-metabolism-
related enzymes activity, regulation of cholesterol metabolism and regulation of 
adipocyte-derived adipokines (52). 
The reported increase in the apoA1 levels is limited, therefore, it is uncertain whether 
quantitative raising apoA1 levels per se, independent of other changes in lipid and/or 
non-lipid risk factors, can have clinical significance for reduction the risk of CVD. Risk 
modification may be due to the correction of inflammation and similar effects might be 
found with other treatments (69). Given the finding of similar efficacy of TNF-α 
inhibitors and rituximab, and the correlation between changes in lipids and 
inflammatory markers in our study, it seems likely that major effect could be related to 
the suppression of inflammation, which is associated, in turn, with increments in apoA1 
and long-term unaltered levels of oxidized LDL. 
The clinical impact of these findings is unclear, and further studies are needed to 
clarify the role of the lipid changes on cardiovascular morbidity in RA. Also, studies 
addressing qualitative lipid disorders during anti-rheumatic therapy are warranted.  
 
4.1.2 Associations with carotid atherosclerosis and CVD 
Paper II. In the early RA patients, the levels of apolipoproteins had not changed at 
the 5-year assessment compared with baseline, whereas the oxLDL levels had 
increased, p=0.000.  
Controlled for age, gender, smoking status and history of CVD/ 
hypertension/diabetes, longitudinal levels of log apoA1 were inversely associated 
with cIMT (ß= -0.24, 95% CI -0.47; -0.02, p=0.047), whereas log apoB/apoA1-ratio 
showed a positive association (ß=0.45; 95% CI 0.04-0.85, p=0.030), thus, the 
reduction in apoA1 by 2.4% (95% CI 0.1-4.6%) or the increase in the apoB/apoA1 
ratio by 4.6% (95% CI 0.3 – 8.9%) corresponded to the increase in cIMT by 0.1 mm. 
Neither levels of log apoB nor oxLDL over-time were significantly related to cIMT.  
Higher levels of apoB and the apoB/apoA1-ratio during the follow-up proved 
independent associations with detection of carotid plaque after five years of RA 
disease, p=0.002, p=0.026, respectively. Then, higher levels of oxLDL over-time 
tended towards a positive association with the plaque presence, p=0.079. 
Paper III. The measures of apolipoproteins at baseline and over the first five years of 
RA disease failed to demonstrate significant associations with the CVD outcomes 
during the follow-up of a mean 12 (2.9) years. By contrast, levels of log oxLDL over-
time, but not at baseline, were higher in individuals who experienced a subsequent 
CVD event compared with those who did not, p=0.027. 
Conclusions and discussion: These results suggest that apolipoproteins are 
independent predictors of cIMT and carotid plaque in patients with RA. To date, 
published data are insufficient to conclude if changes in apolipoproteins, especially in 
apoA1, mirror changes in traditional lipids, and if apolipoproteins are more 
susceptible to fluctuation due to inflammatory changes, or if apolipoproteins may be 
more useful for absolute CVD risk estimation in patients with RA (351). 
A systematic review and meta-analysis have shown that for an absolute cIMT 
difference of 0.1 mm the future risk of myocardial infarction increases by 10% to 
15%, and the stroke risk increases by 13% to 18% in the general population (220). In 
this regard, our results suggest that even small changes in apoA1 and the 
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apoB/apoA1-ratio, by mean of 2.4% and 4.6% respectively, might correspond to a 
clinically significant risk of future CVD.  
Importantly, despite effective control of inflammation, we documented here an 
increase in levels of oxLDL during five years of follow-up after RA disease onset. 
This increase of oxLDL might influence both progression of atherosclerosis and the 
RA disease per se. However, our results were not conclusive about association 
between oxLDL levels and carotid ultrasound measurements. 
Traditional risk factors may behave differently in RA and in the general population. 
Thus, in the large AMORIS-study the predictive value of lipids for AMI and ischemic 
stroke were not consistent in the RA patients (302). However, the non-associations of 
apolipoproteins and the CVD outcome in our study do not exclude a potential 
influence of traditional risk factors for underlying pro-atherogenic mechanisms. Thus, 
the patients who experienced CVD events after RA-onset, compared with those who 
did not, were more frequently classified with hyperlipidaemia or gained increasing 
levels of oxLDL between the study entry and the 5-year assessment. 
In the general population, increasing plasma oxLDL levels are associated with 
increased risk for CVD (343) and predictive for CVD, independently of traditional 
lipids and traditional cardiovascular risk factors (230), as well as for rupture-prone 
atherosclerotic plaques (206). Additionally, serum oxLDL are raised in RA and 
correlate with disease activity independently of other inflammatory markers, 
suggesting the importance of oxLDL in a chronic inflammatory condition per se (187, 
393). Taken together, oxLDL may have significance for CVD outcome probably due 
to plaque instability, but further studies are needed. 
 
4.2   ANTI-PHOSPORYLCHOLINE ANTIBODIES 
4.2.1 Influence of biologic agents 
Paper I. At initiation of biological therapy, there was no statistically significant 
difference in the anti-PC IgM levels between patients started on anti-TNF-α and 
rituximab, or between RF-positive and RF-negative patients. On anti-TNF-α therapy, 
the levels of anti-PC increased significantly already after 3 months, and overall, by 
26% after 12 months, p<0.001, while the levels decreased by 14% on rituximab, 
p=0.023. At all time-points of follow up, the anti-PC levels were significantly higher 
in the anti-TNF treated vs. the rituximab treated patients, p<0.001, independent of 
age, gender and baseline disease characteristics. 
At entry, there were no significant correlations between the anti-PC concentrations 
and levels of inflammatory markers, disease characteristics or apolipoproteins. 
Nonetheless, on both anti-TNF-α and rituximab, patients achieving remission at the 
end of the study (DAS28<2.6), compared with those not in remission, had 
significantly higher baseline anti-PC levels, p=0.007 and p=0.041, respectively. 
Conclusions and discussion: Based on the findings summarized in introduction, it 
has been proposed that the low levels of anti-PC IgM represent an immune-deficient 
state of depressed anti-inflammatory capacity associated with an increased risk of 
chronic inflammatory diseases, for example, atherosclerosis. Also, the low anti-PC 
IgM levels may promote disease activity and disease outbreaks in auto-inflammatory 
condition through insufficiency in anti-inflammatory and anti-apoptotic properties 
(122). In this aspect, the finding that higher anti-PC levels were more common among 
individuals achieving remission in RA, than among patients not in remission after one 
year´s use of biologic agents, raises the question whether measure of anti-PC could 
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identify patients prone to a good therapy response, whether treatment with anti-PC 
may intensify effect of other medications, and whether anti-PC per se may have a 
positive effect in RA.  
The mechanism by which the anti-TNF-α therapy was associated with increasing 
anti-PC IgM levels in the present patients with RA is not clear. One possibility is that 
TNF-α has a direct inhibitory effect on B cells which produce anti-PC (unpublished 
data), but it is also possible that anti-PC is increased indirectly as a consequence of 
decreased inflammatory burden in general. 
While anti-TNF-α treatment has been extensively studied in the context of CVD, 
little is known about the risk of CVD following rituximab in rheumatic disease (250). 
In humans, treatment with rituximab induces an almost complete depletion of 
circulating B cells that usually lasts for 6 to 9 months, and in humans and primates  
persistent partial B-cell depletion may be found also in bone marrow and lymphoid 
organs (280). Theoretically, depletion of B cells in autoimmune diseases should be 
limited to conventional B2 cells while sparing regulatory B10 cells and potentially 
protective B1 cells, producers of natural antibodies (369), but this has not been 
proven in humans.  
The evidence from clinical studies indicates that anti-CD20 therapy targets non-
proliferating short-lived memory B cells and their immediate progeny, responsible for 
production of an array of activity-related autoantibodies, such as RF, ACPA, anti-
dsDNA or anti-neutrophil cytoplasmic antibodies. In contrast, long-lived plasma 
cells, mainly responsible for protective immunoglobulin titers, but only some of the 
auto-reactive IgG antibodies such as Sm, Ro, La and RNP which do not correlate 
with disease activity, are not affected by rituximab (90). Thus, after commencement 
of rituximab, it has been observed a drop in levels of auto-reactive auto-antibodies, 
and also, of overall serum levels of IgG and IgM, in approximately 5% and 20% of 
patients, respectively (41, 42, 60, 62, 102), the latter seems to be mostly pronounced 
following multiple B-cell depletion cycles based on rituximab (75). Interestingly, 
treatment of RA with anti-TNF-α agents has been associated also with a reduction in 
the levels of RF and ACPA antibodies probably through downregulation of the 
production of several inflammatory cytokines and mediators (15).  
Taking into consideration potential changes in serum IgM levels after rituximab 
initiation, it was not unexpected to find decreasing anti-PC IgM levels in the 
rituximab group, but the increasing levels in the anti-TNF-α patients, despite similar 
reductions in disease activity, are challenging. As outlined above, probable 
explanations for the diverse anti-PC courses are inhibition of anti-PC production by 
TNF-α, an effect that is hampered by TNF-α blockade, and decrease of B-cells anti-
PC synthesis by rituximab. Still, it would be preferable to measure parallel both the 
total levels of IgM and anti-PC IgM in the tested samples, and to examine if levels of 
total IgM correlates to levels of anti-PC antibodies.  
 
4.2.2 Association with carotid atherosclerosis  
Paper II. In the early RA patients, the levels of anti-PC IgM antibodies decreased at 
the 5-year assessment compared with baseline, p=0.001. In unadjusted regression 
analyses, the lowest tertile of anti-PC at baseline (≤ 46.6 U/ml) was trend wise 
positively associated with the bilateral carotid plaques presence five years after RA 
onset, while the highest tertile of anti-PC at baseline (≥ 87.0 U/ml) corresponded 
negatively, p=0.054 and p=0.016, respectively. These associations disappeared with 
   31 
adjustment for age and gender. However, in longitudinal analyses, the low anti-PC 
tertile during the first five years of RA disease was associated with an enhanced 
detection of bilateral carotid plaques, p=0.000, independent of age, gender, smoking 
and history of CVD/ hypertension/diabetes. 
Conclusions and discussion: Here we reported that low IgM anti-PC levels over-time 
had an unfavorable association with the plaque presence after five years of RA 
disease. Thus, anti-PC IgM may have an independent role in carotid atherosclerosis in 
patients with RA. This finding is in line with the previous studies where high levels 
of IgM-antibodies against PC have been a strong protection marker for carotid 
atherosclerosis development, measured by cIMT, in hypertensive subjects (339), 
while the low anti-PC levels have been associated with the carotid plaque occurrence 
in a cross-sectional study of patients with SLE (9).  
Further, in the present study the anti-PC IgM levels decreased during the follow-up 
despite amelioration of inflammation measured by conventional methods. This 
finding implies that the low anti-PC levels may potentially characterize an immune-
deficient state and distinguish ongoing, otherwise unrecognized, inflammation in RA. 
 
4.2.3 Association with CVD 
Paper III. In the 105 patients with early RA without history of CVD ahead of RA 
diagnosis (one case contributed only up to 12 months of follow-up before occurrence 
of a CVD event), the baseline levels of anti-PC IgM failed to show any association 
with subsequent CVD events. At the same time, an increasing probability of having 
low levels of anti-PC throughout the first five years after RA diagnosis was 
demonstrated in individuals who experienced subsequent CVD event compared to 
those who did not, p=0.002, independent of age, gender and methotrexate usage. 
Paper IV. In this inception RA cohort, the levels of anti-PC IgM also significantly 
decreased during the first two years of follow-up, p=0.000. The levels of anti-PC both 
at inclusion and after 2 years of observation were lower in participants who 
experienced a subsequent incident CVD event, then, the latter were more likely to be 
in the low anti-PC tertile at RA diagnosis (≤ 42.9 U/ml). The levels of these 
antibodies did not differ between individuals who deceased or survived throughout 
the study period. In the Kaplan-Meier analysis, the CVD event-free survival, but not 
all-cause mortality, was shorter in those having the low anti-PC IgM levels, p=0.024. 
However, multivariate Cox regression tests failed to prove a statistically significant 
association between anti-PC levels and the study outcomes. 
Conclusions and discussion: These findings extend the evidence of an 
atheroprotective role of anti-PC IgM antibodies, while low levels might be an 
independent risk marker for CVD outcomes (118, 154, 314). In paper III the levels of 
natural autoantibodies over-time had a link with incident CVD events, but the initial 
levels of these autoantibodies did not. It seems possible that direct or indirect effect of 
chronic systemic inflammation may be of greater importance for development of 
atherosclerosis and CVD to manifest, but the firm conclusions cannot be drawn from 
a study of a small sample size. As to results in paper IV, the explanation for the lack 
of association of natural antibodies and CVD outcomes after adjustment for age, 
gender and traditional CVD risk factors may imply the significance of conventional 
or other e.g., disease related risk factors for CVD in the complex inflammatory milieu 
of RA. 
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4.3 ASSOCIATION BETWEEN CAROTID MEASURES AND CVD  
Paper III. In the 104 patients with early RA (all cases without CVD ahead of RA 
diagnosis and ahead of carotid ultrasonography at the 5-year assessment), the rate of 
incident CVD events did not differ as regards cIMT measures, but the rate was 
approximately 4-fold increased if bilateral carotid plaques were present compared to 
those without plaque or with unilateral plaque, 4.44 (1.69-7.2) per 100 person-years. 
Also, CVD event-free survival times were shorter for subjects with bilateral carotid 
plaques occurrence compared to those without, corresponding to mean (95% CI), 13.9 
(12.8-15.0) versus 15.2 (14.7-15.8) years, respectively, since study inclusion, p=0.012 
by log-rank test. Then, the bilateral carotid plaques presence, but not cIMT, was 
associated with strictly atherosclerosis-related CVD outcomes (AMI, angina pectoris, 
or ischemic cerebrovascular event), age-adjusted HR 6.31 (1.27-31.4), p=0.025. 
Conclusions and discussion: Here, we confirmed the association between detection 
of the bilateral carotid plaques and a poor CVD-free survival in patients with RA. 
However, the current study did not demonstrate clinical importance of cIMT in 
survival analyses. The lack of association could depend on low power, few 
participants followed for more than 10 years, and the lack of carotid ultrasound 
evaluation at inclusion. Anyway, the presence of traditional risk factors and carotid 
atherosclerosis (both plaque presence and cIMT) were pronounced in those with CVD 
events prior to RA onset, while plaque presence and inflammatory-dependent factors 
were prominent in those with occurrence of CVD events after RA onset. These 
findings may be in line with non-increase in mortality and CVD reported during the 
first 10 years of follow-up in inception RA cohorts (17), probably due to a lead time 
for adverse cardiovascular effects brought about by cumulative inflammation and 
accumulated disability. 
Given discordances in reports on prevalence of carotid plaque and differences in 
cIMT (196), the evidence for increased subclinical atherosclerosis in RA is not 
definitive. More importantly, only few studies have explored measures of subclinical 
atherosclerosis as predictor of CVD events in RA. Reported findings of predictive 
value of cIMT may be related to composition of the population studied and 
unaccounted confounders (104, 142). Further larger studies are needed to legitimize 
the use of subclinical markers of atherosclerosis as outcomes in RA, and whether 
these markers can indicate CVD prognosis.  
 
4.4  RA DISEASE FACTORS, ATHEROSCLEROSIS AND CVD 
4.4.1 Disease measures and carotid atherosclerosis 
Paper II. In this prospective study on 114 patients with early RA, baseline levels of 
disease related factors as ESR, DAS28, tender or swollen joint count and RF 
positivity failed to show statistically significant association with cIMT and plaque 
presence after five years disease. The bilateral carotid plaque presence was positively 
associated with log CRP over-time, but this relation was not verified after adjustment 
for age, gender, smoking status and history of CVD/ hypertension/diabetes.  
Conclusions and discussion: In the present study, neither initial levels nor 
longitudinal development of tested inflammatory markers revealed associations with 
carotid measures, after full adjustment. These negative findings might seem to 
contradict the hypothesis of a correlation between inflammation and progressive 
atherosclerosis (212). Still, the disease activity in RA is suggested to influence mostly 
plaque vulnerability but not cIMT measurements or plaque presence per se (333). Our 
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results, however, indicate that the influence of other factors, e.g., traditional CVD risk 
factors, is substantial and might conceal the effect of other factors. Also, the lack of 
positive associations may arise from methodological issues such as plaque definition 
and ultrasound scanning in different arterial segments, non-high sensitive CRP 
measurement, the frequent use of concomitant glucocorticoids and a small sample 
size. 
 
4.4.2 Disease measures, CVD and mortality 
Paper III. In this study, during a mean follow-up of 12 (2.9) years, the 105 patients 
with early RA, without history of CVD events prior to RA-onset, experienced 17 
CVD events such as AMI, angina pectoris, congestive heart failure or ischemic 
cerebrovascular event, corresponding to an incidence rate of 1.35 events per 100 
person-years (95% CI 0.71-2.0). Improvement in the DAS28, VAS pain and the HAQ 
score over the first year, but not their initial levels, were age-independently associated 
with a better CVD outcome, HRs (95% CI) 0.68 (0.5-0.97), 0.97 (0.95-0.99), 0.35 
(0.15-0.82), and respectively. Then, the higher HAQ score at the 5-year assessment 
was associated with a poorer CVD outcome, HR 2.54 (95% CI, 1.31-4.92), 
independent of age. Other potential confounder factors were not considered as only 
age, but not gender, ever smoking, hypertension, diabetes mellitus or body weight, 
was associated with the risk of the outcome in this study. 
In longitudinal analyses, log CRP, the HAQ score and VAS pain over the five years 
of RA disease showed a different pattern of development as time progressed in 
groups stratified by incident CVD events occurrence or not. Thus, log CRP, the HAQ 
score, and VAS pain were higher in individuals who experienced a subsequent CVD 
event, p=0.038, p=0.007, and p=0.030, respectively. This finding was confirmed after 
further adjustment for age, with the exception of over-time log CRP for which age-
corrected association statistically weakened, p=0.069. 
ESR at entry or during the first five years after RA diagnosis, and RF presence failed 
to demonstrate significant associations with the CVD outcome. 
Paper IV. In this inception RA cohort incorporating the 741 patients with RA 
followed >10 years, there were 177 incident CVD events (AMI, cardiac arrest, angina 
pectoris, coronary bypass grafting or percutaneous coronary intervention, peripheral 
arterial disease, angioplasty or other vascular surgery, ischemic stroke, transient 
ischemic attack) and 151 deaths, corresponding to incidence rates of 2.1 (1.8-2.4) and 
1.7 (1.4-1.9) per 100 person-years, respectively.  
In models adjusted for age, gender, smoking status, hypertension, diabetes mellitus 
and hyperlipidemia, an increased risk for incident CVD events and all-cause mortality 
were associated with AUC measures of CRP and HAQ up to 2 years, and HAQ at 2 
years, corresponding HRs (95% CI) for the CVD outcome: 1.04 (1.00-1.08), 1.14 
(0.99-1.33), and 1.35 (1.05-1.73); and for the mortality outcome: 1.08 (1.04-1.12), 
1.39 (1.19-1.63), and 1.75 (1.35-2.27), respectively. Then, RF positivity, the WBC 
count and the HAQ score at baseline, ESR-AUC, and DAS28-AUC were 
independently related to higher death rates, corresponding HRs (95% CI): 1.61 (1.13-
2.31), 1.07 (1.00-1.13), 1.35 (1.04-1.75), 1.06 (1.01-1.10), and 1.09 (1.01-1.17). On 
the contrary, reduced CVD risk was associated with decline in the HAQ score after 1 
year, and reduced mortality risk with decline in the VAS pain, HRs (95% CI) 0.75 
(0.58-0.97), and 0.75 (0.58-0.97), respectively.  
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Conclusions and discussion: RA may worsen or hasten co-morbidity (263), and the 
results of the current studies also indicate that inadequate control of systemic 
rheumatoid inflammation during the critical first years of disease may have a negative 
impact on future CVD morbidity and survival. The risk of subsequent incident CVD 
events was inversely associated with reductions in the DAS28, HAQ score and VAS 
pain between inclusion and the 1-year assessment, while cumulative measures of 
CRP, ESR, and DAS28 over the first years of RA disease were linked to a poor 
prognosis, the finding that emphasizes the significance of cumulative inflammation 
for CVD outcomes in RA and the detrimental role of insufficient treatment of RA 
during the critical period after diagnosis.  To date, few reports have shown 
relationships of changes in inflammatory and RA disease measures with CVD 
outcomes  (264). 
The present findings are in line with longitudinal inception cohort studies suggesting 
that the course of RA is established early, and that the most important period for 
therapy is the first 1–2 years. Then, baseline markers predictive for worse clinical 
outcomes, such as destructive joint pathology and premature mortality, might 
dissociate from the clinical course following appropriate treatment (34, 202). That the 
CVD risk in RA could be decreased if the RA disease is managed and treated with 
appropriate intensity, has been shown in the COBRA trial in early RA, where early 
intensive treatment compared with initial monotherapy improved the clinical 
outcomes such as survival, co-morbidities and joint damage after 11 years (374). 
Considering these facts, it has been suggested that RA should be controlled and 
monitored tight as diabetes mellitus and hypertension (265). 
We also expanded earlier reports concerning the unfavourable effect of functional 
impairment for CVD morbidity (34, 40, 109, 150, 234, 266, 390, 398). The decline in 
the functional score after one year was linked to a better CVD prognosis, while the 
HAQ burden over the two first years implied a worse CVD outcome. At the same 
time, a higher HAQ score at baseline was related to a less chance of survival, but was 
not associated with CVD prognosis. These findings implicate that the HAQ score has 
differential value for prediction of outcome depending on the time-point in the course 
of RA disease it is measured.  
Consequences of pain persistency in RA disease are not well known. Quality of life is 
significantly impaired in RA, and one of the most important problems is persistent 
pain, attributable to the combined effect of lasting synovitis, progressive joint damage 
and co-morbidities. Chronic pain and pain-related psychiatric illness have been 
shown to have a role in increased CVD related mortality in RA (95, 228). In our 
study, the higher was the reduction in the VAS pain between the time of diagnosis 
and the 1-year assessment the less was the risk for all-cause mortality, independently 
of demographic and traditional CVD risk factors. Although controlling pain is one of 
the indications of successful treatment, and it has been shown that patients given early 
treatment with DMARD or aggressive treatments have markedly reduced pain scores 
(6, 379), still, many patients with early RA continue to suffer more or less persistent 
pain over the course of the disease. Addressing the question of CVD risk 
stratification, evaluation of pain should not be neglected in clinical care of patients 
with RA. 
The next finding in the present study was that the WBC count at RA diagnosis, but 
not baseline CRP or ESR measures, was independently linked to death. To our 
knowledge, the potential role of WBC count to predict CVD and mortality outcome 
has not been explored in early RA. One cross-sectional study has though documented 
that the WBC count, independent of age, gender and disease duration, was predictive 
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of mortality in patients with RA (50). In the general population, prospective studies 
have demonstrated an association between higher WBC count and CVD, death after 
acute coronary syndrome, and all-cause mortality (70, 165, 377).  
Mononuclear cells (monocyte/macrophages, T-lymphocytes) play a central role in the 
pathogenesis of atherosclerosis by ingesting oxidized low-density lipoprotein, 
transforming into foam cells, and recruiting additional monocytes and macrophages 
from the vascular space into the subendothelial layers of large and medium-sized 
arteries. Infiltrates of mononuclear cells are prevalent and pathogenic within unstable 
coronary artery plaques (212). The proliferative activity of promonocytes can be 
increased by relatively mild systemic inflammatory stimuli leading to increase of 
monocytes count in the blood, and at the same time the characteristics of circulating 
monocytes also change (152). Additional studies are warranted to link elevated WBC 
count to increased risk for CVD and mortality in RA, and to evaluate whether WBC 
provides a superior predictive value to other inflammatory measures. 
We recognize that the patients who volunteered for additional assessment with 
ultrasonography (paper III) might be expected to be healthier than those who did not; 
in fact, only one CVD event was registered before the 5-year additional assessment, 
which could have explained, at least partly, low rates of CVD events in that study.  
Also, the incidence rates in the study of a limited sample size could be influenced by 
chance. In the small cohort (paper III), rates for AMI and congestive heart failure 
were found at lower rates, approximately 0.1 and 0.6 per 100 person-years, compared 
with reported 0.5 and 2 per 100 person-years (164, 245). Underestimation of CVD 
rates and self-selection bias, if anything, could result in weaker associations, still, the 
presented results were statistically robust. Besides, our study did not have adequate 
power to detect small but possibly important factors, and the effect size could not be 
accurately estimated. Furthermore, the current results cannot be extrapolated to 
“pure” atherosclerotic disease as definition of cardiovascular outcomes here also 
encompassed outcomes with possible non-atherosclerotic underlying mechanisms, 
such as congestive heart failure. In the present patients we could though exclude non-
ischemic causes to the heart failure such as diabetes, obesity, alcohol abuse, valvular 
heart disease and arrhythmia.  
As to paper IV, the validity of the measurements was demonstrated by the reasonable 
incidence rates of the outcomes and distribution of several established CVD risk 
factors which were generally similar to those previously reported in other western 
inception RA populations (17, 18, 164). This study was prospective in patient 
enrolment and follow-up but was observational in nature and subject to limitation as 
uncorrected confounding, e.g. only information on lipid-lowering treatment was 
available rather than measures of serum lipids. We also used the composite CVD 
outcome, and the reported associations cannot be extrapolated for specific risks of 
coronary, cerebrovascular or peripheral atherosclerotic events. 
 
4.5 IMPACT OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS 
4.5.1  Therapies and carotid atherosclerosis 
Paper II. In these 114 patients with early RA, simple regression analyses showed a 
negative association between cumulative daily dose of methotrexate (MTX) 
(measured over the first five years of disease) and cIMT, p=0.038, but this association 
was not verified after controlling for age and gender. Neither usage of antimalarials or 
cumulative daily dose of glucocorticoids (GC), nor total dose and duration of therapy 
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with MTX or GC showed any statistically significant associations with the outcomes 
of carotid atherosclerosis after five years of RA disease. 
Conclusions and discussion: As discussed before, the major consideration, while 
interpreting the results here, is a limited sample size, frequent use of concomitant 
glucocorticoids, a low number of patients with hypertension and diabetes at entry, 
inclusion of participants with pre-existing CVD, and the lack of ultrasonography 
examination at entry which could influence the estimates. 
 
4.5.2 Associations of therapies with CVD and mortality  
Paper III. In this study of early RA, regular use of drugs as MTX, antimalarials, 
biologic agents, and GC was considered if reported during at least 6 months 
throughout the follow-up. The use of MTX showed a protective role and was age-
independently associated with a better CVD outcome, HR 0.34 ((95% CI, 0.12-0.91), 
hence, a risk reduction of CVD by 66% in those on MTX, while a doubled risk in 
those not treated with MTX. At the same time, regular use of antimalarials, biologic 
agents, or GC did not demonstrate any statistically significant association with the 
CVD outcomes. 
Paper IV. In this large early RA cohort, as in paper III, regular use of drugs was 
considered if it was reported during at least 6 months throughout the follow-up. In 
this study, regular use of GC had an association with a poor CVD outcome, adjusted 
HR (95% CI) 1.65 (1.21-2.26). On the contrary, reduced CVD risk was associated 
with the use of any DMARD or MTX during the first year, or regular use of MTX >6 
months during follow-up, corresponding adjusted HRs (95% CI): 0.63 (0.44-0.90), 
0.72 (0.53-0.97), and 0.72 (0.53-0.99). Then, reduced mortality risk was 
independently associated with the use of biologic agents, HR 0.45 (95% CI, 0.21-
0.98).  
Conclusions and discussion: The findings here largely confirmed and broadened the 
previous reports on the protective value of anti-rheumatic treatments (23, 233), and 
beneficial effect of MTX use for the cardiovascular outcomes (368, 381). The fact 
worth considering is that the patients in these observational studies were treated in 
conventional care during a period before modern aggressive therapies were used. 
Thus, despite higher inflammatory burden measured by CRP-AUC and ESR-AUC 
over the first two years after disease onset, the participants with adverse outcomes 
had less likely been treated with MTX regularly but more likely with GC, and those 
who deceased during follow-up had less likely been prescribed biologic agents (paper 
IV). 
The role of GC in the occurrence of CVD and increased mortality in patients with RA 
is more or less controversial, and both beneficial and harmful effects have been 
recognized (72, 137). Though confounding by indication was not accounted, the 
finding in paper IV supports the evidence linking low-dose GC therapy with adverse 
CVD outcomes.  
Then, use of biologic agents was shown to be associated to a decrease of estimated 
mortality risk, a result that however cannot be considered definite owing to 
confounding by indication/contraindication and a low number of events in analysis. 
Though biological therapy is typically considered for more severe RA disease, patient 
selection could have produced protective effect of biologicals in the current study. 
However, it is worth bearing in mind the possibility of a better survival due to 
effective control of systemic inflammation (197). Long-term controlled trials with 
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randomized treatment allocation are needed in order to accurately assess the effects of 
biologic agents on atherogenesis and cardiovascular risk. 
 
4.6 AGE AT ONSET OF RA AND RISK OF CVD AND MORTALITY 
Paper IV. In these patients with early RA who had been followed for more than 10 
years, the disease characteristics in the age groups, <65 years at RA onset vs. ≥ 65 
years, were statistically similar with regard to distribution of RF positivity, the WBC 
count, the VAS pain and the HAQ scores at baseline, HAQ after two years of disease, 
and frequency of DMARD started at baseline, use of MTX and GC the first year, and 
regular use of GC during observation. The older participants, compared to the 
younger ones, had though less often ACPA antibodies, had higher baseline measures 
of CRP, ESR, DAS28, and were less often treated with MTX or biologic agents 
regularly. 
Cox regression models in the age groups, adjusted for age, gender, smoking status, 
hypertension, diabetes and hyperlipidemia, showed that only in the younger 
individuals, RF or ACPA positivity, WBC count, CRP-AUC, ESR-AUC, and VAS-
pain-AUC (measured over the first two years) were associated with a higher CVD 
risk, corresponding adjusted HRs (95% CI) 2.72 (1.48-5.02), 1.87 (1.01-3.34), 1.07 
(1.01-1.14), 1.10 (1.02-1.17), and 1.06 (1.00-1.13). On the other hand, only in the 
elderly, reductions in CRP, ESR, and HAQ after one year, and regular use of MTX 
were associated with a lower risk of incident CVD event, corresponding adjusted HRs 
0.94 (0.89-1.00), 0.90 (0.82-0.97), 0.71 (0.52-0.97), 0.64 (0.43-0.96), while regular 
use of GC heightened the risk of CVD, HR 1.69 (1.13-2.51). 
As to the mortality outcome, similarly, in the younger patients, RF or ACPA 
positivity, WBC count at baseline, and VAS pain-AUC were associated with a higher 
risk of death, respective adjusted HRs (95% CI) 2.26 (1.09-4.68), 2.14 (1.05-4.35), 
1.10 (1.01-1.20), and 1.09 (1.01-1.16). In the elderly patients, DAS28-AUC, and use 
of GC during the first year heightened the risk of death, adjusted HRs (95% CI) 1.10 
(1.01-1.21), and 1.47 (1.00-2.20), respectively, while reductions in DAS28 and VAS 
pain after one year were associated with a lower risk of death, adjusted HRs (95% CI) 
0.88 (0.78-0.99), and 0.93 (0.86-1.00), respectively. 
Conclusions and discussion: The definition of early and late onset RA used in 
previous studies ranges from 45 years to 75 years; our distinction of age groups was 
pragmatic and carried out before the statistical analyses. It has been reported that in 
the elderly, the RA disease is characterized by a greater proportion of men than in the 
younger (female-to-male ratio, 1.5–2:1 versus 4–4.5:1 in the younger patients), often 
an insidious onset, frequent constitutional symptoms and involvement of the proximal 
limb joints, particularly the shoulder girdle, and remitting seronegative symmetrical 
synovitis. Laboratory testing may reveal a striking inflammatory response with an 
elevated ESR and mild anemia associated with chronic disease, but incidence of RF-
positivity is low. Disease activity is usually more marked, with higher swollen and 
tender joint counts, a longer duration of morning stiffness, and greater alterations in 
quality of life indices (185, 329, 394). Thus, disease characteristics of the elderly 
participants in our study were for the most part typical. 
To date, prognosis of RA in the elderly is unclear. Here, we explored the influence of 
age at RA onset on predictive models of adverse CVD outcome and mortality in early 
RA. Generally, in the younger patients the inflammatory burden (calculated as AUC 
over the first two years of disease) was shown to be associated with the study 
outcomes, whereas in the older patients the improvements in CRP, ESR, and DAS28 
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between baseline and the 1-year assessment predicted outcome. These differences 
between age groups might have an explanation in the fact that in the elderly 
inflammation is common as a consequence of many causes, the burden of which 
disappears in statistically analyses when adjusted for age. Still, CRP-AUC and ESR-
AUC were linked to death in both age groups, but numerically the associations were 
attenuated in the older population with more risk factors. These results imply that 
different longitudinal approaches may be of importance in studies validating 
prognostic factors in RA. Age stratification could improve evaluation of risk factors 
for CVD and mortality in early RA. 
The key association between age at symptom onset and clinical outcomes relates to 
the rate of progression of RA disease and atherosclerosis. Higher age at symptom 
onset is likely to be associated with a faster rate of increasing morbidity, and thus, a 
poor prognosis. The results of the current study, that in the older patient group the 
reductions in CRP, ESR, and DAS28 after one year was protective, suggest that there 
is a special urgency to get disease activity under control in this age group as they have 
less reserve to cope with inflammation and added disability. 
In our analyses, association between RF, ACPA positivity and adverse outcomes was 
found only in the participants aged <65 years at diagnosis but not in the older 
patients. The inconsistency of previous reports on the role of seropositivity for 
prediction of clinical outcomes in RA may depend on variety of age and absolute risk 
of the outcome in the studied populations and the degree to which other risk factors 
are included in analyses. Studies in which predictive associations with the CVD or 
mortality outcomes were reported tend to include relatively young participants (390), 
while an absence of an association may reflect the older age and heavy risk factor 
burden of the predominantly minor cohorts (34).  
Additionally, in the younger patients, similarly to measures of the inflammatory 
burden, VAS pain-AUC was independently associated with enhanced mortality. 
Then, both the HAQ score after 2 years and HAQ-AUC were predictive for mortality 
in both age groups. Our findings and the recent report on the lowest probability of 
long-term disability if persistent remission is achieved (298) highlight the concern 
about functional impairment also in younger patients, and the importance of treatment 
to target in all ages in early RA. 
As to therapies, only in the elderly, regular GC use was associated with an increased 
risk of adverse CVD and mortality outcomes, while MTX use again showed a 
favorable role for CVD prognosis. Relatively limited published data are available on 
treatment of elderly patients with RA. Observational studies on the use of DMARDs 
has showed no significant difference between the older and the younger patients with 
regard to efficacy, side effects and discontinuation of DMARDs (67, 267), and 
reported minimal toxicity related to treatment (357). Thus, MTX should have a 
prominent role in the management of RA in older patients.   
Older patients with RA, especially those with early disease, are usually responsive to 
treatment with low-dose GC, and the rapid dramatic improvement of symptoms 
experienced with such a low dose along with substantially reduced rate of joint 
destruction (189) shifts the risk-to-benefit ratio in favor of using steroids as first-line 
agents in the elderly. On the other hand, a poor CVD and survival prognosis, 
confirmed in the current study, should be considered. A single case-control study has 
previously evaluated the effect of immunosuppressive treatment (defined as a 
prescription for these agents within the 90 days prior to the time of the first 
cardiovascular event) on the risk of CVD events (hospitalization for AMI and stroke) 
specifically in patients with elderly onset RA, and disclosed an increased risk of CVD 
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events in patients on GC therapy, odds ratio (OR) for GC monotherapy: 1.5 (95% CI, 
1.1–2.1), for GC combination therapy: OR 1.3 (95% CI, 0.8-2.0), and for 
immunosuppressive agents other than MTX with both monotherapy and combination 
treatment, OR 1.8 (95% CI, 1.1-3.0) (325). 
 
4.7 GENERAL REMARKS 
Although our results are intriguing in light of prior research, the potential strengths 
and limitations of the studies merit consideration. The principal strengths are an 
applicable longitudinal approach with prospective structured measurement of RA 
disease related factors and a broad range of biomarkers at disease onset and through 
the first years of disease, long duration of follow-up and comprehensive (inpatient 
and outpatient) data sources. All participants had a clinical diagnosis of RA made by 
a rheumatologist and all patients met the ACR criteria for RA. The BARFOT study 
database consists of typical patients treated within conventional care and seen across 
a variety of settings allowing a wide spectrum of RA. The BARFOT cohort more 
likely retained patients with milder disease, allowing generalizing from the findings 
of the studies. The incident RA design, in which exposure time begins at the time for 
diagnosis and start of  systemic immunosuppressive, allows for a more valid 
comparison of treatments than mixing early with established disease in the same 
analysis. The studies emphasize that systemic inflammation can be assessed using 
standard routinely collected laboratory and clinical measures, providing a simple tool 
to monitor disease activity and, specifically, the response to treatment, which can be 
used as an important tool for risk stratification. The validity of our results is 
demonstrated by the reasonable incidence rates of the clinical outcomes and 
distribution of several established CVD risk factors which were generally similar to 
those previously reported in other western RA populations, therefore, the present 
findings should have wider relevance.  
It is possible that the patients undergoing ultrasonography were different from the 
reference group of RA patients. It could be speculated that sub-clinical CVD disease 
might have been present already at enrolment, which might have biased our findings 
in favor of a positive relationship between biomarker levels and outcomes, but this 
confounding could have affected only estimation of a small number of adverse 
outcomes closer to the time of enrolment.  
The major limitation is the lack of a control group and randomization to therapy.  
Several CVD risk factors and drug prescribing in these observational studies were 
influenced by the RA disease severity itself. Without random assignment of 
treatment, the pure impact of the inflammatory factors on the CVD and mortality risk 
could not be estimated, and it is difficult to infer causation between the treatments of 
interest and outcome risk. Further, we could not provide information about the 
cumulative dose of MTX and GC therapy or duration of therapy in all studies; 
besides, several immunosuppressive medications were commonly used in 
conjunction.  
Although the observational nature of the current studies generally limits the 
conclusions of causality, nonetheless, the results provide important hypothesis-
generating observations. Future large cohort studies and mechanistic studies are 
needed to confirm the findings. 
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5 PERSPECTIVES FOR THE FUTURE 
Atherosclerosis and CVD are major causes of morbidity and mortality in RA. Even 
with the plethora of new therapies, there has not been much improvement in this risk. 
Although we do not fully understand what causes accelerated atherosclerosis 
progression, evidence strongly suggests that the complex interplay between 
dysfunctional immune regulation, inflammation, traditional risk factors, defective 
vascular repair, and therapeutics used to treat the underlying RA disease influence this 
process. A comprehensive biomarker panel incorporating inflammatory, RA disease 
and traditional CVD risk factors could be an essential tool for identifying patients at 
risk of accelerated atherosclerosis soon after diagnosis of RA. Clinical biomarkers 
predictive for poor cardiovascular outcomes are unmet needed. The clinical complexity 
of inflammation and accelerated atherosclerosis will probably require an integrated 
approach to identify and treat at-risk patients.  
Atherosclerosis and RA disease are processes that take place over-time, like the effects 
of the risk factors assumed to influence them. The cross-sectional studies may have 
limited ability to estimate the temporal relationships of over-time changes of exposure 
variables. The potential for the future in this question is larger observational trials in 
inception RA cohorts incorporating longitudinal assessment of systemic inflammation 
and probably new imaging techniques to identify inflamed rupture-prone lesions. Along 
with physical examination and laboratory tests, simple qualitative patient-self reported 
measures should be directed more attention in research and follow-up of patients with 
RA. Larger, prospective, long-term, preferably randomized placebo-controlled studies 
are needed to elucidate the immune-inflammatory mechanisms behind progression of 
atherosclerotic disease in RA. 
Although the world of research is drawing a clearer picture of the kind of patient who 
might develop CVD, it is still challenging how to determine a patient at the greater risk. 
For the future, the task is to identify subsets of RA patients who are at heightened risk 
of premature atherosclerosis based on clinical identifiers. For the present, close 
adherence to guidelines for primary cardiovascular prevention and a lower threshold for 
more aggressive interventions in RA are warranted. 
  
   41 
6 CONCLUSIONS IN SHORT 
 
• The increase in anti-atherogenic apolipoprotein A1 after commencement of 
biological therapy (anti-TNF-α and anti-CD20 agents) in RA is not agent-
specific and parallel a reduction in RA disease activity, and may have a 
potential for at least short-term improvement in cardiovascular risk; 
• The atheroprotective natural IgM antibodies against phosphorylcholine (anti-
PC) increase during one year treatment of RA with TNF- inhibitors, but 
decrease with the anti-CD20 therapy, which may have implications for 
cardiovascular risk and RA disease per se; 
• At initiation of biologic agents to patients with RA, the low levels of anti-PC 
IgM antibodies predict an inferior clinical response after one year; further 
studies are needed to examine whether the low levels of these antibodies 
feature an immune-deficient state associated with promote disease activity and 
progression of other chronic inflammatory diseases such as atherosclerosis; 
• The levels of apolipoprotein A1 over-time are negatively, while 
apolipoprotein B and the ratio of apolipoprotein B/apolipoprotein A1 are 
positively associated with carotid atherosclerosis in RA, independent of 
traditional cardiovascular risk factors, which suggest that apolipoproteins are 
independent predictors of atherosclerosis and may be useful in cardiovascular 
risk estimation in patients with early RA; 
• In patients with RA, the bilateral carotid plaque occurrence is associated with 
a poor CVD prognosis, which may have implication for the clinical 
cardiovascular risk assessment; 
• Low levels of natural anti-PC IgM are associated with the carotid plaque 
occurrence in RA, which extended earlier reports on atheroprotective role of 
these antibodies; 
• Low levels of anti-PC IgM antibodies and increasing levels of oxidized LDL 
during the first years after RA diagnosis may link chronic inflammation in RA 
to an enhanced cardiovascular risk, and they might serve as indicators of a 
subsequent CVD event; 
• In early stages of RA, the cumulative burden of inflammation and the 
presence of RA disease related autoantibodies have a predictive value for 
CVD and mortality in the younger patients, while a change in inflammatory 
markers may have an augmented predictive value in the older patients, which 
propose that age stratification could improve evaluation of risk factors for 
CVD and mortality in early RA; 
• The progressive decline in physical function is associated with poor survival 
in both younger and older patients with early RA, which highlights the 
concern about functional impairment in all ages; 
• In patients over 65 years old at RA onset, low-dose glucocorticoids may 
heighten CVD and mortality risks, which further supports the concern about 
potential long-term undesirable reactions to glucocorticoid therapy in the 
elderly; 
• Early improvement in inflammation, pain and functional disability as well as 
use of methotrexate are associated with a better CVD prognosis, which 
emphasizes the appreciation for the need to treat RA early and more 
aggressively to reduce cardiovascular disease and improve long-term 
outcomes. 
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7 SVENSK SAMMANFATTNING 
Reumatoid artrit (RA), så kallad ledgångsreumatism, är en kronisk inflammatorisk 
ledsjukdom som har påvisats vara förknippad med en minst 1.5-2-faldig riskökning 
för hjärt-kärlsjuklighet (CVD) och en förkortad livslängd. Ateroskleros, 
åderförkalkning, har liksom RA sjukdomen karaktären av en kronisk inflammatorisk 
process och är orsak till CVD. Uppkomst och utveckling av RA och ateroskleros har 
ansetts vara nära förenade. De klassiska riskfaktorer för hjärtkärlsjukdom i 
befolkningen, som rökning, diabetes, högt blodtryck och höga blodfetter, har inte med 
säkerhet samma stora betydelse hos RA patienter. Det tycks att den gemensamma 
inflammatoriska processen spelar en viktig roll men att även andra faktorer kan bidra. 
Huvudsyftet med denna avhandling var att undersöka ytterligare mekanismer bakom 
den förtidiga aterosklerosutvecklingen vid RA och försöka identifiera markörer som 
skulle kunna indikera risken att få CVD och dö. 
I studierna har vi koncentrerat oss på RA sjukdomsrelaterade mått och riskfaktorer för 
CVD av betydelse för både inflammation och utveckling av ateroskleros. Bland dessa 
märks apolipoproteiner, oxiderat LDL-kolesterol (oxLDL) och skyddande naturliga 
antikroppar som riktas mot phosphorylcholine på oxLDL och döda kroppsceller (anti-
PC). Apolipoprotein A1 (apoA1) finns i det ”goda” kolesterolet som skyddar 
kärlväggen och våra perifera vävnader från överskott av kolesterol. Apolipoprotein B 
(apoB) finns i de aterogena ”onda” lipidpartiklarna. Överskott på apoB partiklar i 
förhållande till apoA1 partiklar, d.v.s. en hög kvot apoB/apoA1, anses öka den 
aterogena belastningen på kärlväggen och risk för CVD. 
På senare år har biologiska läkemedel, som t.ex. TNF-α blockerare och B-cells terapi, 
börjat användas i allt större utsträckning för behandling av RA. Data är inte entydiga 
avseende inverkan av dessa läkemedel på riskfaktorer för CVD. Vi fann att 
behandling med TNF-α blockerare (162 patienter med RA) eller B-cells terapi (53 
patienter med RA) ledde till ökande halter av den anti-aterogena apoA1 parallellt med 
sjunkande sjukdomsaktivitet under ett års uppföljningstid. ApoB och den aterogena 
kvoten påverkades inte av behandlingarna. Dessa effekter kan vara gynnsamma och 
motverka utvecklingen av aterosklerosprocessen. Vidare fann vi att i TNF-α gruppen 
ökade halter av skyddande anti-PC medan de sjönk i B-cells gruppen. Dessa resultat 
talar således för potentiellt både positiva och negativa effekter avseende risk för 
CVD. Betydelsen av biologiska läkemedel för risk att få CVD ska följas noggrant och 
undersökas vidare i kommande studier. 
Förutom prospektiv mätning av riskmarkörer i blodet, har 114 patienter med tidig RA 
undersökts med ultraljud avseende förekomst av åderförkalkning i halskärl fem år 
efter att diagnosen RA ställts. Vi fann att apoB, den aterogena kvoten och låga halter 
av anti-PC var förknippade med åderförkalkningen, medan apoA1 innebar skyddande 
effekter. Det kan tolkas som att apolipoproteiner och anti-PC har en viktig roll i 
aterosklerosutvecklingen hos RA patienter. Vidare uppföljning av samma patienter 
mer än 10 år efter RA sjukdomens debut visade att de patienter som hade 
åderförkalkningen/plaque hade högre risk att få CVD jämfört med patienter som hade 
negativ ultraljudsfynd, alltså kan ultraljudsundersökningen av halskärl användas som 
riskindikator för CVD hos patienter med RA. Vad gäller sjukdomsrelaterade faktorer 
var den risken att insjukna i CVD statistiskt lägre om den inflammatoriska aktiviteten, 
smärtan och den dagliga fysiska förmågan hade förbättrats ett år efter RA diagnosen 
eller om behandling med metotrexat (ett av de vanligaste läkemedlen mot 
inflammation vid RA) hade använts. De som löpte större hjärtkärlrisk var de patienter 
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som hade låga halter av anti-PC eller stigande halter av oxLDL under fem första åren 
efter RA diagnosen. 
I en stor kohort av patienter med RA som följts sedan diagnossättandet (741 personer) 
mättes kliniska utfall (CVD sjukdom och dödlighet) mer än 10 år efter 
sjukdomsdebuten. Det visade sig att riskfaktorer skiljde sig åt beroende på åldern vid 
RA sjukdomens debut - före eller efter 65-årsåldern. För yngre patienter hade bördan 
av inflammatoriska faktorer över två första åren av RA sjukdomen och förekomsten 
av RA specifika autoantikroppar större prediktivt samband med kliniska utfall, medan 
för äldre patienter var förbättringen i inflammatoriska markörer första året närmare 
knuten till minskningen i antalet händelser. Liksom i den föregående studien 
framkom det att behandling med metotrexat hade skyddande effekter, medan 
användning av lågdoserade glukokortikoider var knuten till sämre klinisk prognos hos 
de äldre RA patienterna. Resultaten pekar alltså på att uppdelningen efter åldern vid 
RA sjukdomens debut kan tillföra ytterligare information för bedömning av en 
enskild individs hjärtkärlriskprofil. För att förbättra överlevnad vid RA tycks en tidig 
och effektiv behandling vara avgörande.  
Riskbedömning för CVD hos patienter med RA är ett komplext beslutsbärande 
problem där uppföljning av sjukdomsmått, behandlingsresultat, bieffekter av terapier 
och biokemiska markörer ska vägas in tillsammans med de traditionella 
riskfaktorerna. 
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